Any concurrent chemotherapy, immune therapy, biologic, hormonal therapy for cancer treatmentXx_NEWLINE_xXHave any approved or investigational anti-cancer therapy, including chemotherapy or hormonal therapy, with exceptions: Hormone-replacement therapy or oral contraceptivesXx_NEWLINE_xXPrior chemotherapy, targeted small molecule therapy, or radiation therapy within two weeks prior to registration for protocol therapy; Note: If the subjects have undergone major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting protocol therapyXx_NEWLINE_xXAny approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3 weeks prior to initiation of study treatmentXx_NEWLINE_xXOther anticancer or experimental therapy; no other experimental therapies (including chemotherapy, radiation, hormonal treatment, antibody therapy, immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, matrix metalloprotease inhibitors, thalidomide, anti-vascular endothelial growth factor [VEGF]/fetal liver kinase 1 [Flk-1] monoclonal antibody or other experimental drugs) of any kind are permitted while the patient is receiving study treatmentXx_NEWLINE_xXThe patient has received chemotherapy, radiotherapy (except for palliative reasons), immunotherapy, or targeted therapy for gastric cancer within 3 weeks of study treatmentXx_NEWLINE_xXNo previous radiotherapy, chemotherapy or other brain tumor directed therapy other than corticosteroid therapy and surgeryXx_NEWLINE_xXAny prior treatment for the current breast cancer, including chemotherapy, hormonal therapy, radiation or experimental therapyXx_NEWLINE_xXAll adjuvant or neoadjuvant chemotherapy, radiation, and surgery completed at least 21 days prior to registration\r\n* All triple negative patients must receive chemotherapy of the treating physician’s choice\r\n* ER/PR+ patients must receive chemotherapy (of the treating physician’s choice) unless Oncotype Dx or another genomic predictor score indicates that they are at low or intermediate risk of disease recurrence with endocrine therapy alone\r\n* Patients may have breast reconstruction during protocol participation, but definitive breast cancer surgery must be completed at least 21 days prior to registration\r\n** Concomitant biologic therapy, hormonal therapy, and bisphosphonates are acceptableXx_NEWLINE_xXPrior adjuvant treatment with chemotherapy and/or endocrine therapy, as determined by the treating physician, is allowed; the last dose of chemotherapy or radiation therapy must be at least 30 days prior to study registration; concurrent hormonal therapy will be allowedXx_NEWLINE_xXPatients must not currently be receiving any other investigational agents or any other systemic anti-cancer therapy (including radiation, excluding RANKL inhibitors and bisphosphonates); in event patient recently received any other systemic anti-cancer therapy, patient must be off therapy at least 7 days prior to registration and any therapy-induced toxicity must have recovered to =< grade 1, except alopecia and =< grade 2 neuropathy which are allowed; any planned radiation therapy must be completed before enrollment onto S1609Xx_NEWLINE_xXTreatment for this cancer including surgery, radiation therapy, chemotherapy, biotherapy, hormonal therapy or investigational agent prior to study entryXx_NEWLINE_xXPatients must not be planning to receive any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment; concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptableXx_NEWLINE_xXPatients must not be planning treatment with other systemic anti-cancer agents (e.g., chemotherapy, hormonal therapy, immunotherapy) or other treatments not part of protocol-specified anti-cancer therapy including concurrent investigational agents of any typeXx_NEWLINE_xXNo prior medical therapy (chemotherapy, immunotherapy, biologic or targeted therapy) or radiation therapy for the current colon cancer except for one cycle of mFOLFOX6Xx_NEWLINE_xXPatients must not be planning to receive concomitantly other biologic therapy, hormonal therapy, other chemotherapy, surgery or other anti-cancer therapy except radiation therapy while receiving treatment on this protocol; however, patients receiving extended adjuvant endocrine therapy for an earlier ER positive breast cancer treated with curative intent and without recurrence for at least 5 years may continue with their endocrine therapyXx_NEWLINE_xXNo treatment with chemotherapy, radiation therapy, immunotherapy, biological therapy, hormonal therapy, or other thiazolidinediones (TZDs) =< 21 days before study registrationXx_NEWLINE_xXChildren who have previously received chemotherapy, radiation therapy or any anti-leukemic therapy are not eligible for this protocol, with the exception of cytarabine for the treatment of TMDXx_NEWLINE_xXPatients must not be planning to receive concomitant other biologic therapy, radiation therapy, hormonal therapy, other chemotherapy, anti-cancer surgery or other anti-cancer therapy while on this protocolXx_NEWLINE_xXPatients must not be planning to receive concomitant other biologic therapy, radiation therapy, intravesical chemotherapy, surgery, or other therapy while on this protocolXx_NEWLINE_xXPatients must not be planning to receive concomitant biologic therapy, hormonal therapy, chemotherapy, surgery, or other cancer therapy while on studyXx_NEWLINE_xXPatients must not have received any prior chemotherapy, radiation therapy, or other therapy for the treatment of ALL (other than those noted below) and must not be receiving any immunosuppressive therapy; patients may not have received any prior investigational therapy within 28 days prior to registration; patients must not have received any monoclonal antibody therapy within 42 days of registration; patients may have received the following within any time prior to registration: low dose chemotherapy-including: cyclophosphamide 1 g/m^2, oral 6-mercaptopurine, or oral methotrexate (other low dose chemotherapy may be allowable, however any other options not listed here should be confirmed with the study chairs), TKI therapy, steroids, hydroxyurea, leukapheresis, intrathecal chemotherapy or vincristine (vincristine sulfate)Xx_NEWLINE_xXPrior chemotherapy or tumor directed therapy (i.e. radiation therapy, biologic agents, local therapy (embolization, radiofrequency ablation, and laser); therefore, patients with a pre-disposition syndrome who have a prior malignancy are not eligibleXx_NEWLINE_xXAnti-cancer treatment including surgery, radiotherapy, chemotherapy, other immunotherapy, or investigational therapy within 14 days of registrationXx_NEWLINE_xXAt least 4 weeks since prior treatment (chemotherapy, radiation therapy, hormonal therapy)Xx_NEWLINE_xXThe last dose of prior systemic therapy (e.g. chemotherapy, targeted therapy etc) or radiation therapy (with the exception of palliative radiotherapy) was received less than 14 days prior to the first day of treatmentXx_NEWLINE_xXConcurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatmentXx_NEWLINE_xXhormonal therapyXx_NEWLINE_xXTreatment with any of the following therapies: \r\n* Radiation therapy, surgery or tumor embolization within 14 days prior to the first dose of pazopanib hydrochloride OR\r\n* Chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanib\r\n* Patients who require chronic use of strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers including but not limited to grapefruit juiceXx_NEWLINE_xXBiologic therapyXx_NEWLINE_xXImmunotherapyXx_NEWLINE_xX2. Any concurrent chemotherapy, radiotherapy, immunotherapy, or biologic therapy for cancer treatment. Concurrent use of hormones for non-cancer related conditions is acceptable (e.g., insulin for diabetes & hormone replacement therapy). Local treatment of isolated lesions for palliative intent is acceptable;Xx_NEWLINE_xXTreatment with chemotherapy, hormonal therapy (except hormone replacement therapy, oral contraceptives), immunotherapy, biologic therapy, radiation therapy (except palliative radiation to bony metastases), or herbal therapy as cancer therapy within 4 weeks prior to initiation of DHES0815AXx_NEWLINE_xXThe most recent cytotoxic, biologic or non-hormonal targeted therapy received must have been completed at least 21 days prior to study treatmentXx_NEWLINE_xXTreatment with any of the following anti-cancer therapies =< 14 days prior to registration:\r\n* Radiation therapy\r\n* Surgery or tumor embolization\r\n* Chemotherapy, immunotherapy\r\n* Biologic therapy\r\n* Investigational therapy\r\n* Hormonal therapyXx_NEWLINE_xXSystemic chemotherapy/radiotherapy/investigational therapy within 14 days (with the exception of hydroxyurea and/or dexamethasone, or one dose of cytarabine) prior to starting therapyXx_NEWLINE_xXConcurrent use of any other anti-cancer therapy, including chemotherapy, targeted therapy, immunotherapy, or biological agentsXx_NEWLINE_xXNo other concurrent investigational agents or other meningioma-directed therapy (chemotherapy, radiation) while on studyXx_NEWLINE_xXExpansion Phase: Initially, only immunotherapy naïve subjects who have progressed on first-line cytotoxic chemotherapy or who have declined first-line treatment with cytotoxic chemotherapy will be enrolled. Subjects with no prior systemic anti cancer therapy (i.e. first line therapy) may be enrolled in a second cohort if approved by the SMC. Subjects previously treated with systemic adjuvant therapy, other than immunotherapy for recurrent advanced NSCLC, are also eligible.Xx_NEWLINE_xXPrevious anti-cancer chemotherapy, immunotherapy or investigational agents =< 28 days prior to registrationXx_NEWLINE_xXAny systemic anti-cancer therapy within 3 weeks prior to C1D1 of study therapy, with the following exception:\r\n* Any prior investigational anti-cancer therapy and/or monoclonal antibody is not permitted within 4 weeks of C1D1Xx_NEWLINE_xXTreatment with any systemic anti-neoplastic therapy, or investigational therapy within the 4 weeks prior to the initiation of study drug.Xx_NEWLINE_xXParticipant received anticancer therapy including chemotherapy, immunotherapy, radiotherapy, biologic, or any investigational therapy within 21 days before Study Day 1; participant received palliative radiotherapy or small molecule targeted anti-cancer agents within 14 days of Study Day 1.Xx_NEWLINE_xXTreatment with radiation therapy, surgery, chemotherapy, or investigational therapy within one month prior to study entry (6 weeks for nitrosoureas or Mitomycin C).Xx_NEWLINE_xXPrior neoadjuvant chemotherapy, endocrine therapy, or biologic therapy for current breast cancer [Period 2]Xx_NEWLINE_xXPrior immunotherapy is allowed.Xx_NEWLINE_xXPrior biologic therapy:\r\n* Patients must have discontinued all biologic or investigational therapy at least 21 days before registrationXx_NEWLINE_xXTreatment with any anti-cancer therapy, including radiotherapy, chemotherapy, biologic therapy. Prior therapy with weekly paclitaxel for recurrent disease, unless administered more than 2 years prior to enrollment, unless part of an upfront treatment strategy.Xx_NEWLINE_xXUse of any investigational agent. Use and/or receipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal anti-bodies) within 14 days prior to the first dose of study therapy.Xx_NEWLINE_xXParticipants who have received prior systemic therapy (chemotherapy or targeted therapy) within 7 days of Study Day 1 or those who have not recovered from clinically significant adverse events due to agents administered more than 7 days earlier. (continuation of the same regimen of HER-2 antibody targeted therapy agents, hormonal therapy and treatment with bisphosphonates or denosumab are permitted)Xx_NEWLINE_xXChemotherapy, Tyrosine Kinase Inhibitor therapy, radiation therapy or hormonal therapy within 2 weeksXx_NEWLINE_xXImmunotherapy or biological therapy, or investigational agent within 3 weeks (Note: some cohort exceptions allow anti-PD-1 therapy)Xx_NEWLINE_xXCompletion of other cancer therapy (targeted therapy, chemotherapy, investigational therapy, immunotherapy, radiotherapy, surgery) 14 days prior to first dose of protocol therapy\r\n* For patients with breast cancer only:\r\n** May continue ongoing antiestrogen therapy (for example, aromatase inhibitor)\r\n** May continue ongoing human epidermal growth factor receptor (Her)2 directed therapy (for example, trastuzumab)Xx_NEWLINE_xXAny anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatmentXx_NEWLINE_xXHave not fully recovered from the acute toxic effects of prior anticancer therapy (e.g., chemotherapy, immunotherapy, radiation therapy) or are currently receiving cytotoxic chemotherapy, immunotherapy or radiation therapy. A minimum period of 4 weeks / 28 days is required between the end of prior anticancer therapy and the initiation of TB-403.Xx_NEWLINE_xXPatient has not recovered from adverse events due to chemotherapy, immunotherapy, or radiation therapy administered more than 28 days prior to first administration of study drug.Xx_NEWLINE_xXConcurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than study treatment (regorafenib, other agents being investigated in combination with regorafenib)Xx_NEWLINE_xXConcomitant treatment with other anti-neoplastic agents (hormonal therapy acceptable)Xx_NEWLINE_xXConcurrent immunotherapy is allowedXx_NEWLINE_xXOther active malignancy requiring therapy such as radiation, chemotherapy, or immunotherapy.Xx_NEWLINE_xXHas received the prohibited therapy (e.g., concurrent anti-cancer therapy including but not limited to: chemotherapy, radiation, hormonal, or immunotherapy) ?14 days prior to first planned dose of AC0010MA.Xx_NEWLINE_xXConcurrent or planned systemic chemotherapy, radiotherapy, new hormonal or anti- HER2 directed therapy directed at management of breast cancer (existing anti-HER2 therapy can be continued as recently recommended in the National Consensus Guidelines)Xx_NEWLINE_xXAny major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 21 days prior to study day 1, or daily or weekly chemotherapy without the potential for delayed toxicity within 14 days prior to study day 1Xx_NEWLINE_xXRadiation therapy, chemotherapy, immunotherapy, investigational therapy or corticosteroid use within 2 weeks of or after eligibility-defining bone marrow biopsy. Bisphosphonates and denosumab are permitted if subject has been receiving for at least 90 daysXx_NEWLINE_xXPrior therapy: Patients must have discontinued all chemotherapy, investigational therapy or biologic therapy at least 14 days prior to initiating study treatment (with the exception of trastuzumab for patients with HER2+ breast cancer)Xx_NEWLINE_xXPatients may not receive any cancer-directed concurrent therapy, such as concurrent chemotherapy, radiotherapy, or hormonal therapy while on studyXx_NEWLINE_xXHave discontinued all previous therapies for breast cancer (including chemotherapy, radiotherapy, immunotherapy, and investigational therapy), except for ongoing corresponding combination therapy, for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug(s), and recovered from the acute effects of therapy (until the toxicity resolves to either baseline or at least Grade 1) except for residual alopecia or peripheral neuropathy. For Part F and H: concurrent treatment with trastuzumab emtansine (T-DM1) is not allowed.Xx_NEWLINE_xXPatients who have had immunotherapy, chemotherapy or radiotherapy within 14 days prior to the first dose of navitoclax, or prior systemic anti-cancer therapy (chemotherapy with delayed toxicity, extensive radiation therapy, immunotherapy, biologic therapy, or vaccine therapy) within the last 3 weeks prior to first dose of dabrafenib and/or trametinib; chemotherapy regimens without delayed toxicity within the last 2 weeks preceding the first dose of study treatment; biologics will not be allowed within 30 days prior to, or during, navitoclax administrationXx_NEWLINE_xXConcurrent non-protocol-specified anti-tumor therapy (e.g., chemotherapy, other targeted therapy, topical therapy such as 5-fluorouracil or imiquimod, radiation therapy, surgery, or photodynamic therapy\r\n* For patients with multiple cutaneous BCCs at baseline that are not designated by the investigator as target lesions, treatment of these non-target BCCs with surgery may be permitted but must be discussed with data coordinator prior to any surgical procedureXx_NEWLINE_xXPrior treatment of this cancer including:\r\n* Surgery\r\n* Radiation therapy\r\n* Chemotherapy\r\n* Biotherapy\r\n* Hormonal therapy \r\n* Investigational agent prior to study entryXx_NEWLINE_xXRecovery from effects of recent surgery, radiotherapy, or chemotherapy\r\n* Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration; continuation of hormone replacement therapy is permitted\r\n* Any other prior therapy directed at the malignant tumor, including immunologic agents, must be discontinued at least three weeks prior to registration; if the prior therapy was with bevacizumab then at least 4 weeks after treatment discontinuation must have elapsed prior to treatment on this studyXx_NEWLINE_xXSubject has received anti-cancer chemotherapy, immunotherapy, hormonal (with the exception of hormones for thyroid conditions or estrogen replacement therapy [ERT], or any investigational therapy) within 21 days of enrollmentXx_NEWLINE_xXBiologic (anti-neoplastic agent): at least 7 days since the completion of therapy with a biological agentXx_NEWLINE_xXAt least 3 weeks from prior systemic treatments including investigational anti-cancer therapy, radiation therapy; and have recovered from prior toxicitiesXx_NEWLINE_xXSubjects must not have had prior RT, chemotherapy (including Gliadel wafer), immunotherapy or therapy with a biologic agent, or hormonal therapy.Xx_NEWLINE_xXParticipant has received anti-cancer traditional medicine or anti-cancer herbal remedies within 14 days prior to ABBV-744 dosing. Saw palmetto is considered anti-cancer herbal remedy. Participant with CRPC who has received anti-cancer therapy including chemotherapy, immunotherapy, radiotherapy, biologic or any investigational therapy within a period of 21 days prior to Study Day 1. Participant with AML has received anti-cancer therapy within a period of 14 days or 5 half-lives (whichever is longer; except for immunotherapy where a period of 21 days will be acceptable) prior to Study Day 1. Except for hydroxyurea which will be allowed during screening and treatment for controlling leukocytosis for AML subjects.Xx_NEWLINE_xXSubjects must have recovered from all toxicity associated with previous chemotherapy, targeted therapy, experimental therapy, biological therapy, immuno-oncology therapy, surgery, radiotherapy, or other locoregional therapy. (Exception: Subjects may enter with continuing alopecia.) The following intervals must elapse between end of last treatment and receiving the first dose of SM08502:Xx_NEWLINE_xXAny concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment.Xx_NEWLINE_xXAny chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks of the first dose of mRNA-4157 or pembrolizumabXx_NEWLINE_xXRequire concomitant chemotherapy, radiation therapy, or immunotherapy. Hydroxyurea is allowed up to the evening before starting (but not within 12 hours) of starting Induction therapy.Xx_NEWLINE_xXTreatment including radiation therapy, chemotherapy, or targeted therapy, for the currently diagnosed breast cancer prior to randomization.Xx_NEWLINE_xXAny anti-cancer therapy, including chemotherapy or hormonal therapy, within 2 weeks prior to initiation of study treatmentXx_NEWLINE_xXCompletion of all previous therapy (including surgery, radiotherapy, chemotherapy, immunotherapy, or investigational therapy) for the treatment of cancer ?3 weeks before the start of study therapy.Xx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational; prior therapy with bisphosphonates is allowed; prior radiation therapy to a solitary plasmacytoma is allowedXx_NEWLINE_xXHad immunotherapy, radiotherapy, radioimmunotherapy, biological therapy, chemotherapy, or treatment with an investigational product within 4 weeks prior to treatment initiation (or oral therapy within 1 week prior to treatment initiation).Xx_NEWLINE_xXConcomitant anticancer therapy, systemic immune therapy, or hormonal therapy as cancer therapyXx_NEWLINE_xXConcurrent administration of other cancer specific therapy or investigational agents during the course of this study is not allowedXx_NEWLINE_xXPrior systemic therapy: patients must be at least 2 weeks from prior chemotherapy, biological agents, immunotherapy or any investigational drug product, with adequate recovery of toxicityXx_NEWLINE_xXAny prior anti-cancer chemotherapy, biologic or investigational therapy for PDAC.Xx_NEWLINE_xXConcurrent anticancer therapy (e.g. chemotherapy, radiation therapy, biologic therapy, immunotherapy, hormonal therapy, investigational therapy)Xx_NEWLINE_xXPrior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks of study Day 1 or not recovered from adverse events caused by a previously administered agentXx_NEWLINE_xXNo other anticancer-therapy (chemotherapy, immunotherapy, hormonal anti-cancer therapy, radiotherapy [except for palliative local radiotherapy]), biological therapy or other novel agent is to be permitted while the patient is receiving study medication; patients on luteinizing hormone-releasing hormone (LHRH) analogue treatment for more than 6 months are allowed entry into the study and may continue at the discretion of the investigatorXx_NEWLINE_xXNo prior chemotherapy, biologic therapy, hormonal therapy or investigational therapy for this operable breast cancerXx_NEWLINE_xXPatients who are currently being treated with cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy) other than the trial therapy.Xx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational; prior therapy with bisphosphonate is allowed; prior radiation therapy to a solitary plasmacytoma is allowedXx_NEWLINE_xXNaive to prior systemic anti-cancer therapy for melanoma (example: chemotherapy, hormonal therapy, targeted therapy, immunotherapy, or other biologic therapies) except adjuvant treatment with interferon (IFN), interleukin (IL)-2, or vaccine therapies or herbal therapiesXx_NEWLINE_xXConcomitant chemotherapy, radiation therapy, or immunotherapyXx_NEWLINE_xXConcurrent therapy with other systemic anti-neoplastic or investigational agentsXx_NEWLINE_xXPatient has received prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1Xx_NEWLINE_xXNeed for treatment with any conventional modality for prostate cancer (surgery, radiation therapy, and hormonal therapy)Xx_NEWLINE_xXNo more than two prior lines of cytotoxic-containing chemotherapy regimens for advanced disease. There is no limit for prior targeted therapy, hormonal therapy and immunotherapy (such as nivolumab).Xx_NEWLINE_xXOther concurrent chemotherapy, radiotherapy, or any ancillary therapy considered investigational\r\n* NOTE: Bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatmentXx_NEWLINE_xXPatients must have had no radiotherapy, immunotherapy, chemotherapy or therapy with targeted agents within the last 1 monthXx_NEWLINE_xXPatients who have had prior chemotherapy, immunotherapy, targeted therapy, or radiotherapy within 1 month of enrollmentXx_NEWLINE_xXAt least 3 weeks must have passed since any prior anti-tumor therapies including chemotherapy, radiation therapy or any other anti-cancer treatmentsXx_NEWLINE_xXAntitumor therapy (chemotherapy, antibody therapy, molecular-targeted therapy, retinoid therapy, or investigational agent) within 14 days or 5 half-lives of day 1Xx_NEWLINE_xXPrior therapy with any systemic therapy (chemotherapy or biologic therapy) within twenty-eight days prior to study entryXx_NEWLINE_xXConcurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than study treatment (regorafenib, other agents being investigated in combination with regorafenib)Xx_NEWLINE_xXConcurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than study treatment; the washout period between radiation therapy or tumor embolization is two weeks; given the refractory nature of the study population, the washout period between study treatment and prior chemotherapy or biological therapy, will be three weeks prior to use of regorafenibXx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation)Xx_NEWLINE_xXAny approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3 weeks prior to initiation of study treatment, with the exceptions stated in the protocolXx_NEWLINE_xXConcurrent chronic systemic immunotherapy, chemotherapy or hormone therapyXx_NEWLINE_xXPatients must be at least 4 weeks from previous therapy (chemotherapy, hormonal therapy, and radiation therapy, or investigational agents; 6 weeks for mitomycin C)Xx_NEWLINE_xXPatients receiving other treatment for breast cancer (includes standard hormonal therapy, chemotherapy, biologic therapy, immunotherapy, or radiation therapy). Patients receiving chronic bisphosphonate or denosumab therapy are eligible.Xx_NEWLINE_xXCurrently receiving cancer therapy (chemotherapy, radiation therapy, immuno- therapy, biologic therapy, hormonal therapy, surgery, and/or tumour embolization).The following are allowed: Hydroxyurea for proliferative disease, Corticosteroids, Use of hematopoetic growth factors is permitted at the discretion of the investigator according to published guidelines (e.g., National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), etc.). The following are NOT allowed: Investigational anti cancer drug within 2 weeks prior to the first dose of GSK525762; Major surgery, radiotherapy, or immunotherapy within 4 weeks of GSK525762 Chemotherapy regimens with delayed toxicity within the last 4 weeks. Chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within the last 2 weeks. Nitrosourea or mitomycin C within the last 6 weeksXx_NEWLINE_xXOther concurrent chemotherapy, or any ancillary therapy considered investigational; NOTE: bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatmentXx_NEWLINE_xXPatients may not be receiving any other investigational agents during protocol therapy, or up to 30 days prior to beginning protocol therapy; there should be a least a 1-week interval between last dose of endocrine therapy and protocol therapy, and at least 3 weeks for the last dose of biologic therapy (eg, bevacizumab) or cytotoxic therapy (or 2 weeks for capecitabine or weekly paclitaxel, 6 weeks for mitomycin-C and nitrosoureas), and adequately recovered from adverse effects from prior therapy to meet all other eligibility criteriaXx_NEWLINE_xXIf they are undergoing or have undergone in the past 4 weeks (28 days) any other therapy for their cancer, including radiation therapy and adjuvant therapyXx_NEWLINE_xXHas received chemotherapy, immunotherapy, biologic therapy or endocrine therapy within the past 12 weeksXx_NEWLINE_xXA minimum of 4 weeks will be required from any prior therapy, including chemotherapy, immunotherapy and/or radiation; in addition, recovery to grade 1 or less from all reversible toxicities related to prior therapy is required at study entryXx_NEWLINE_xXPatients who are receiving any other investigational or concurrent anticancer treatment (chemotherapy, radiotherapy, immunotherapy, cytokine therapy except erythropoietin) at the time of enrollment except for testosterone lowering therapy in men with prostate cancerXx_NEWLINE_xXNo prior hormonal therapy for lung cancerXx_NEWLINE_xXNo concurrent anticancer therapy. Required washout from prior therapy:\r\n* Endocrine therapy: no required wash-out\r\n* Chemotherapy: 14 days\r\n* Major surgery: 14 days (provided wound healing is adequate)\r\n* Radiation: 7 days\r\n* Investigational/biologic therapy (half-life =< 40 hours): 14 days\r\n* Investigational/biologic therapy (half-life > 40 hours): 28 days.Xx_NEWLINE_xXPatients must not be planning to receive concomitantly other biologic therapy, hormonal therapy, other chemotherapy, surgery or other anti-cancer therapy except radiation therapy while receiving treatment on this protocol.Xx_NEWLINE_xXIs receiving concurrent chemotherapy, investigational drug, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non–cancer-related conditions (e.g., hormone replacement therapy) is acceptable.Xx_NEWLINE_xXConcurrent chemotherapy or targeted anti-cancer agents, other than intrathecal therapyXx_NEWLINE_xXOther concurrent chemotherapy, or any ancillary therapy considered investigational ? 14 days prior to study registration; NOTE: Bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatmentXx_NEWLINE_xXAny approved anti-cancer therapy including chemotherapy, targeted small molecule therapy or radiation therapy within 2 weeks prior to trial Day 0 as well as current participation or recipient of treatment on a clinical trial within 28 days prior to Day 0;Xx_NEWLINE_xXSubjects with concurrent cytotoxic chemotherapy or radiation therapy; there must be at least 28 days between any other prior chemotherapy (or radiotherapy) and study treatment; prior antibody therapy must be discontinued 8 weeks prior to start of study treatmentXx_NEWLINE_xXImmunotherapy, chemotherapy, radiotherapy, or investigational therapy within 6 months prior to drug dosingXx_NEWLINE_xXAny prior therapy directed at the malignant tumor, including radiation therapy, chemotherapy, and biologic/targeted agents must be discontinued at least 28 days prior to tumor resection for preparing TIL therapy.Xx_NEWLINE_xXPatients may not have received chemotherapy, targeted therapies, biologic response modifiers and/or hormonal therapy within the last 14 daysXx_NEWLINE_xXPatients may not be receiving any other investigational agents, or concurrent biological therapy, chemotherapy, or radiation therapyXx_NEWLINE_xXPrior cytotoxic chemotherapy or biologic therapy for prostate cancerXx_NEWLINE_xXTreatment with prohibited medications (concurrent anticancer therapy including chemotherapy, radiation, hormonal treatment [except corticosteroids and megesterolacetate], or immunotherapy) =< 14 days prior to treatment with osimertinibXx_NEWLINE_xXChemotherapy, targeted therapy, growth factors or radiation therapy within 14 days of C1D1Xx_NEWLINE_xXPatients receiving any concurrent chemotherapy, radiotherapy, immunotherapy, or biologic, or hormonal therapy for cancer (concurrent use of hormones for noncancer-related conditions [e.g., insulin for diabetes and hormone replacement therapy] is acceptable) Patients must have completed any previous cancer-related treatments before enrolment. The following intervals between the end of the prior treatment and first dose of study drug must be observed:Xx_NEWLINE_xXCompletion of all previous therapy (including surgery, radiotherapy, chemotherapy, immunotherapy, or investigational therapy) for the treatment of cancer ?1 week before the start of study therapy.Xx_NEWLINE_xXUse of any chemotherapy, investigational agents, immunotherapy, or hormonal therapy other than GnRH agonists within 28 days of the start of treatment on protocol. Use of bone targeted agents including bisphosphonates and RANK ligand inhibitors is allowed if on stable dose; Xgeva or Zometa cannot be started within 28 days of initiating study therapy.Xx_NEWLINE_xXMust be at least 4 weeks since treatment with standard or investigational chemotherapy, biochemotherapy, surgery, radiation, cytokine therapy, any monoclonal antibodies or immunotherapy, and recovered from any clinically significant toxicity experienced during treatmentXx_NEWLINE_xXHas had any systemic anti-cancer therapy (includes anti-VEGF therapy or any systemic investigational anti-cancer agent)Xx_NEWLINE_xXPatients currently on cytotoxic chemotherapy or immunotherapy are eligible, not including anti-VEGF therapyXx_NEWLINE_xXPrior anti-cancer therapy as specified below: At least 28 days from enrollment must have elapsed from any prior systemic inhibitory/stimulatory immune checkpoint molecule therapy (eg, ipilimumab, nivolumab, pembrolizumab, atezolizumab, OX40 agonists, 4-1BB agonists, etc). Note: Patients who experienced immune -related pneumonitis, pituitary or thyroid dysfunction, or pancreatitis while on treatment with immune-oncology agents will be excluded; Other anti-cancer therapy (chemotherapy, antibody therapy, molecular targeted therapy, or investigational agent) within 14 days prior to enrollment; Radiation therapy completed within 14 days prior to enrollment; Prior CAR T therapy or other genetically modified T cell therapy.Xx_NEWLINE_xXAny approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to the initiation of study treatment. The following exceptions are allowed: hormone-replacement therapy or oral contraceptivesXx_NEWLINE_xXPatients who have had chemotherapy, hormonal therapy (except LHRH agonist or antagonist), immunotherapy, radioisotope therapy, or RT within 21 days prior to start of the study agentsXx_NEWLINE_xXAny anticancer therapy within 14 days prior to the first dose of study drug, including: small molecules, immunotherapy, chemotherapy, monoclonal antibody therapy, radiotherapy or any other agents to treat cancer (anti-hormonal therapy given as adjuvant therapy for early-stage estrogen receptor (ER) positive breast cancer is not considered cancer therapy for the purpose of this protocol)Xx_NEWLINE_xXMonoclonal antibody based anti-cancer therapy within 28 days prior to study entry or small-molecule based anti-cancer therapy (targeted therapy or chemotherapy) within 14 days prior to study entry.Xx_NEWLINE_xXAny concurrent chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer treatmentXx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, radiotherapy or investigational therapy except for hormonal therapy (e.g., tamoxifen, etc.).Xx_NEWLINE_xXReceived cytotoxic chemotherapy, radiation therapy, or targeted therapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within 28 days of study enrollment.Xx_NEWLINE_xXChemotherapy, targeted small molecule therapy, radiotherapy, experimental agents, prior therapy with anti-tumor vaccines or other immune-stimulatory antitumor agents, or biological cancer therapy (including monoclonal antibodies) within 14 days prior to the start of study drug, or not recovered (=< grade 1 or baseline) from adverse events due to a previously administered agentXx_NEWLINE_xXPatients who relapse on therapy other than standard ALL maintenance therapy must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study\r\n* Cytotoxic chemotherapy: At least 7 days must have elapsed since the completion of cytotoxic therapy (other than standard ALL maintenance therapy) with the exception of hydroxyurea, which is permitted up to 24 hours prior to the start of protocol therapy\r\n* Nitrosoureas: At least 42 days must have elapsed since administration of nitrosoureas\r\n* Hematopoietic growth factors: At least 14 days after the last dose of long acting hematopoietic growth factor (e.g. Neulasta) or 7 days for short acting growth factor (e.g. Neupogen)\r\n* Radiation: At least 84 days must have elapsed since administration of craniospinal, hemipelvic or other radiation therapy to more than 25% of the bone marrow containing spaces; at least 42 days must have elapsed if other substantial marrow radiation has been given\r\n* Nelarabine prior therapy: Patients who have previously been treated with nelarabine are eligible, however if they have previously received a regimen of nelarabine, cyclophosphamide and etoposide, they are not eligible\r\n* Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair\r\n* Immunotherapy: At least 42 days after the completion of any type of immunotherapy (e.g. tumor vaccines or chimeric antigen receptor T cell (CART) therapy\r\n* Monoclonal antibodies: Monoclonal antibodies: At least 3 half-lives of the antibody must have elapsed after the last dose of a monoclonal antibody\r\n* Stem cell infusion: No evidence of active graft versus (vs.) host disease and at least 84 days must have elapsed after transplant or stem cell infusion\r\n* Study specific limitations on prior therapy: Patient may not have previously received therapy with an mTOR inhibitor\r\n* Prior intrathecal therapy: Patients may be enrolled on study regardless of the timing of prior intrathecal therapy; however, they MAY NOT BEGIN TREATMENT ON THIS PROTOCOL UNTIL A MINIMUM OF 7 DAYS HAS ELAPSED SINCE PRIOR INTRATHECAL THERAPYXx_NEWLINE_xX14 day wash-out period from any previous chemotherapy, targeted therapy or radiotherapy, 21 day washout period from previous immunotherapyXx_NEWLINE_xXConcurrent administration of other anti-cancer therapy within 14 days of starting protocol therapy and during the course of this studyXx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, or any ancillary antitumor therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation)Xx_NEWLINE_xXPatients must not have received prior radiation therapy, chemotherapy, immunotherapy or therapy with biologic agents (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, TIL, LAK or gene therapy), or hormonal therapy for their brain tumor; glucocorticoid therapy is allowedXx_NEWLINE_xXNo concurrent chemotherapy or targeted small molecule therapyXx_NEWLINE_xXCurrent treatment with chemotherapy or radiation therapy; any prior therapy directed at the malignant tumor, including biologic and immunologic agents, must be discontinued at least three weeks prior to registrationXx_NEWLINE_xXPatients must have no had adjuvant therapy for the management of endometrial carcinoma; this includes chemotherapy, chemotherapy and radiation therapy, and/or consolidation/maintenance therapy; chemotherapy administered in conjunction with primary radiation as a radio-sensitizer WILL be counted as a systemic chemotherapy regimen; this also pertains to hormonal, vascular, and targeted therapy for the management of endometrial cancerXx_NEWLINE_xXPatients may not be receiving the concomitant administration of any systemic therapy, biologic therapy, or other agents with anti-tumor activity against prostate cancer while the patients are on study.Xx_NEWLINE_xXAny concurrent chemotherapy, investigational product (IP), biologic, or hormonal therapy for cancer treatment; concurrent use of hormonal therapy for non-cancer-related conditions (eg, hormone replacement therapy) is acceptableXx_NEWLINE_xXReceipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) =< 14 days of registrationXx_NEWLINE_xXDisease not amenable to standard treatment (nonresectable or disease present after one or more surgeries and/or sandostatin treatment) or subject has failed existing first line chemotherapy, biologic therapy, targeted agent therapy or radiation therapyXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, monoclonal antibody therapy, or radiation therapy within 2 weeks prior to on-study date\r\n* Note: If currently receiving hormonal therapy or chemotherapy, this treatment must be stopped at least 2 weeks prior to on-study date; hormonal therapy may be restarted after the restaging scan 1 month after the 8th BATs infusion\r\n* Note: Radiation therapy to the axial skeleton must be completed at least 2 weeks prior to on-study dateXx_NEWLINE_xXAny prior myeloma-directed therapy including cytotoxic chemotherapy, biologic therapy, or radiotherapy within 2 weeks of enrollmentXx_NEWLINE_xXWithin 28 days before first dose of protocol-indicated treatment:\r\n* Anti-cancer treatment including chemotherapy, radiation, hormonal therapy, targeted therapy, immunotherapy, or biological therapy\r\n* Major surgery requiring general anesthesia; (Note: within this time frame, placement of a central line or portacath is acceptable and does not exclude)\r\n* Receipt of an investigational agentXx_NEWLINE_xXAny other anticancer therapy (e.g., chemotherapy, biologic therapy, immunotherapy, targeted therapy, endocrine therapy, radiation therapy, intravesical therapy, investigational agent) within 28 days of the first dose of study therapy (and within 6 weeks for nitrosourea or mitomycin C) other than a single dose of intravesical chemotherapy which is permitted between 28 days and 14 days prior to the first dose of study treatmentXx_NEWLINE_xXAny anti-cancer therapy including chemotherapy, hormonal therapy, or radiotherapy within 2 weeks prior to initiation of study treatment; or herbal therapy intended as anti-cancer therapy within 1 week prior to initiation of study treatmentXx_NEWLINE_xXHad within 2 weeks prior to the first dose of study treatment, received prior chemotherapy, targeted small molecule therapy, or radiation therapy, or who has not recovered from adverse events due to a previously administered agent or major surgeryXx_NEWLINE_xXConcurrent anticancer non protocol directed therapy (e.g. chemotherapy, radiation therapy, biologic therapy, immunotherapy, hormonal therapy, investigational therapy)Xx_NEWLINE_xXThe subject has received cytotoxic chemotherapy, molecular targeted therapy, or immunotherapy within 21 days before the first dose of study drug (trametinib)Xx_NEWLINE_xXPatient can have had prior treatment for HCC including prior surgery, radiation therapy, local-regional therapy (abalation or arterial directed therapies), and systemic therapy including sorafenib or chemotherapy (but not anti-PD-1 or anti-CTLA-4 therapy)Xx_NEWLINE_xXChemotherapy, immunotherapy, targeted therapy, monoclonal antibodies, tumor embolization, or other investigational agent within 28 days prior to the first dose of study drugXx_NEWLINE_xXFinished their active cancer treatment (surgery, chemotherapy [chemo] and or radiation) at least 3 months prior to registration; (anti hormonal therapy will not prevent patient from participation as long as he/she can perform mild to moderate physical activities)Xx_NEWLINE_xXPatients who have had anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies or other investigation agents), large field radiotherapy, or major surgery must wait 4 weeks after completing treatment prior to entering the studyXx_NEWLINE_xXReceipt of the last dose of anti-cancer therapy (immunotherapy, endocrine therapy [e.g., abiraterone acetate, enzalutamide], targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) =< 28 days prior to the first dose of study drug. (with the exception of any previous treatment with a PD1 or PD-L1 inhibitor, including durvalumab or an anti-CTLA4, including tremelimumab.)Xx_NEWLINE_xXhave received chemotherapy, hormonal therapy, biologic therapy, immunotherapy or radiation therapy within 14 days prior to the planned start of study treatment.Xx_NEWLINE_xXPrior systemic chemotherapy, immunotherapy, or biological therapy, radiation therapy and/or surgery are allowed; prior use of systemic methotrexate > 1 month prior to study entry is allowed. Intrathecal methotrexate is allowed prior to and during treatment per investigator discretion.Xx_NEWLINE_xXAny concurrent chemotherapy, investigational product (IP), biologic or hormonal therapy for cancer treatment; concurrent use of hormonal therapy for non-cancer-related conditions (e.g. hormone replacement therapy) is acceptableXx_NEWLINE_xXConcomitant use of any anti-cancer therapy or radiation therapyXx_NEWLINE_xXAny of the following for the treatment of cancer within 2 weeks of first study treatment: chemotherapy, immunotherapy, experimental therapy, or biologic therapyXx_NEWLINE_xXOngoing radiation therapy, chemotherapy, hormonal therapy directed at the tumor, immunotherapy, or biologic therapy, including investigational agents for their diseaseXx_NEWLINE_xXConcomitant use of other anti-cancer therapy (chemotherapy, immunotherapy, hormonal therapy (hormone replacement therapy is acceptable), radiotherapy (except for palliative), biological therapy or other novel agent) or live virus and live bacterial vaccines while the patient is receiving study medication. Strong or moderate CYP3A inhibitors and inducers should not be taken with study treatment; however, if no other suitable alternative concomitant medication is available, dose reductions may be allowed under careful monitoringXx_NEWLINE_xXCurrently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy) or investigational anti-cancer drugXx_NEWLINE_xXPrior systemic therapy (chemotherapy, biologic, or immunotherapy) for the same OPSCC. Prior chemotherapy, biologic therapy, and radiotherapy is allowed in patients with loco-regional recurrent disease, if administered at least 6 months prior to study enrolmentXx_NEWLINE_xXPatients should not have received any systemic therapy (including chemotherapy, biologic therapy or immunotherapy) =< 7 days prior to treatmentXx_NEWLINE_xXAny approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment; the following exceptions are allowed:\r\n* Palliative radiotherapy for bone metastases or soft tissue lesions should be completed > 7 days prior to baseline imaging\r\n* Hormone-replacement therapy or oral contraceptivesXx_NEWLINE_xXHas received therapy for this current diagnosis of breast cancer including endocrine therapy or chemotherapyXx_NEWLINE_xXPrior biologic therapy: Patients must have discontinued all biologic therapy at least 21 days before registrationXx_NEWLINE_xXMajor surgery, radiotherapy, chemotherapy, biologic therapy, immunotherapy, experimental therapy within 3 weeks prior to the first dose of the study drugXx_NEWLINE_xXFOR ALL PHASES (Ib AND II): Concurrent therapy with any other non-protocol anti-cancer therapyXx_NEWLINE_xXPrior therapy:\r\n* Any number of prior chemotherapy regimens and/or targeted therapies and/or prior external beam radiation therapy and/or prior hormonal therapy for endometrial cancer are allowed provided the last treatment was > 4 weeks prior to registration\r\n* Vaginal brachytherapy may have been administered at any time prior to registrationXx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (used for a non-Food and Drug Administration [FDA] approved indication and in the context of a research investigation)Xx_NEWLINE_xXDONOR: Receiving any investigational agents, or concurrent biological, chemotherapy, immunosuppression or radiation therapyXx_NEWLINE_xXReceipt of the last dose of anti-cancer therapy (cytotoxic chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) =< 28 days prior to the first dose of study drug (28 days prior to the first dose of study drug for subjects who have received prior tyrosine kinase inhibitors [TKIs] [e.g., erlotinib, gefitinib and crizotinib] and within 6 weeks for nitrosourea or mitomycin C [if sufficient wash-out time has not occurred due to the schedule or pharmacokinetic [PK] properties of an agent, a longer wash-out period may be required])Xx_NEWLINE_xXPatients with plans to receive other concomitant local therapy (including standard fractionated radiotherapy and surgery) or other systemic therapy (including chemotherapy, target therapy and other type of immunotherapy or investigative agents) while on this protocol, except at disease progression, are not eligibleXx_NEWLINE_xXOngoing radiation therapy, chemotherapy, hormonal therapy, immunotherapy, or biologic therapy directed at the tumor; those patients with a plexiform neurofibroma requiring treatment will be eligibleXx_NEWLINE_xXTreatment with any chemotherapy, radiation therapy, biologics for cancer, or investigational therapy within 28 days of first administration of study treatmentXx_NEWLINE_xXAt least 3 weeks from previous cytotoxic chemotherapy or radiation therapy and at least 5 half-lives or 6 weeks, whichever is shorter, after targeted or biologic therapy excepting prior treatment with CTLA 4, PD-1, or PD-L1 blocking antibodies for which only a 2 week interval is required. Patients with prostate cancer, unless orchiectomy has been performed in them, may continue to receive androgen deprivation therapy (ADT), anti-androgen therapy or therapy that interferes with androgenic stimulation.Xx_NEWLINE_xXConcomitant therapy with any of the following: IL-2, interferon or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; or other investigational therapies.Xx_NEWLINE_xXTreatment with other investigational agents including chemotherapy, immunotherapy, or radiation therapy within a month prior to the start of this clinical trialXx_NEWLINE_xXCurrently receiving chemotherapy, radiation therapy, investigational immunotherapy, or investigational biotherapy for breast cancerXx_NEWLINE_xXPatients receiving other concurrent cancer therapy including chemotherapy, immunotherapy, or biologic therapyXx_NEWLINE_xXOther ongoing systemic therapy for cancer, including any other experimental treatment; these include concomitant therapy with any of the following: IL-2, interferon, ipilimumab, pembrolizumab, nivolumab, or other immunotherapy; cytotoxic chemotherapy; and targeted therapiesXx_NEWLINE_xXPrior systemic anti-cancer treatment (chemotherapy, immunotherapy, biologic therapy, vaccine therapy, or investigational treatment) within the last 3 weeks, or chemotherapy without delayed toxicity within the last 2 weeks preceding the first dose of the combination; prior systemic treatment in the adjuvant setting is allowedXx_NEWLINE_xXPrior biological cancer therapy, targeted therapy, or major surgery within 28 days prior to first dose of therapyXx_NEWLINE_xXReceipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, gamma-knife, other investigational agent) =< 14 days prior to the first dose of study drug; for WBRT, the washout period is 28 days; local treatment of isolated lesions for palliative radiation therapy (RT) (by radiotherapy, for example) is acceptableXx_NEWLINE_xXAny concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatmentXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy for the current diagnosis of EGCXx_NEWLINE_xXHas recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy\r\n* Myelosuppressive chemotherapy: At least 3 weeks since completion (6 weeks for nitrosourea)\r\n* Biologic (anti-neoplastic agent): At least 7 days since completion of therapy with a biologic agent\r\n* Radiation (XRT): ? 1 week must have elapsed from prior palliative XRT to non-target lesionsXx_NEWLINE_xXPatient who has had chemotherapy, radiation, hormonal, or biological cancer therapy within 28 days prior to the first dose of study drugXx_NEWLINE_xXReceipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) =< 28 days prior to the first dose of study drug (=< 21 days prior to the first dose of study drug for subjects who have received prior tyrosine kinase inhibitors (TKIs) [e.g., erlotinib, gefitinib and crizotinib] and =< 6 weeks for nitrosourea, mitomycin C, or bevacizumab). (If sufficient wash-out time has not occurred due to the schedule or pharmacokinetics (PK) properties of an agent, a longer wash-out period may be required.)Xx_NEWLINE_xXCurrently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy) or investigational anti-cancer drugXx_NEWLINE_xXPrior chemotherapy, immunotherapy, radioactive, or biological cancer therapy (including monoclonal antibody [mAb]) within 28 days prior to registrationXx_NEWLINE_xXPatients who have had chemotherapy (including investigational cytotoxic chemotherapy), biologic agents (e.g. targeted therapy or antibodies) or radiotherapy within 4 weeks prior to the first dose of study treatmentXx_NEWLINE_xXPrior therapy: there is no limit to the number of prior therapies provided all eligibility criteria are met; however, patients must have recovered from the acute toxic effects of all prior treatment\r\n* Patients must not have received prior therapy with either gemcitabine or nab-paclitaxel\r\n* Myelosuppressive chemotherapy: patients must not have received myelosuppressive chemotherapy within 3 weeks of protocol therapy on this study\r\n* Hematopoietic growth factors: 7 days must have elapsed from the start of protocol therapy since the completion of therapy with filgrastim, and 14 days must have elapsed from the start of protocol therapy after receiving pegfilgrastim\r\n* Biologic (anti-neoplastic agent): 7 days must have elapsed from the start of protocol therapy since the completion of therapy with a biologic agent\r\n* Monoclonal antibodies: 3 half-lives must have elapsed from the start of protocol therapy since prior therapy that included a monoclonal antibody\r\n* Radiotherapy: 2 weeks must have elapsed from the start of protocol therapy since local palliative radiation therapy (XRT) (small port); 3 months must have elapsed if 50% radiation of pelvis; 6 weeks must have elapsed if other substantial bone marrow irradiation was given\r\n* Stem cell transplant or rescue: no evidence of active graft versus (vs.) host disease and 2 months must have elapsed from the start of protocol therapy since transplantXx_NEWLINE_xXReceipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) =< 21 days prior to the first dose of study drugXx_NEWLINE_xXPatients may not be receiving any other investigational agents, or concurrent biological therapy, chemotherapy, or radiation therapyXx_NEWLINE_xXPatients may not be receiving any other investigational agents, or concurrent biological therapy, chemotherapy, or radiation therapyXx_NEWLINE_xXOther concurrent chemotherapy, or any ancillary therapy considered investigational; NOTE: Bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatmentXx_NEWLINE_xXChemotherapy/systemic therapy, radiotherapy, immunotherapy or surgery =< 21 days prior to registration or kinase inhibitor therapy =< 14 days prior to registration or failure to recover from toxicities (to grade 1 or below) from treatment; NOTE: concurrent therapy with octreotide is allowed providing that tumor progression on this therapy has been demonstrated; concurrent therapy with bisphosphonates (e.g. zoledronic acid) or denosumab is also allowed; NOTE: an unlimited number of prior chemotherapeutic or biologic therapies for malignant pheochromocytoma or paraganglioma is permitted; this includes prior anti-angiogenesis therapies such as tyrosine kinase inhibitorsXx_NEWLINE_xXPatients may not be receiving any other investigational agents, or concurrent parenteral biological, chemotherapy, or radiation therapy; oral chemotherapeutic agents or biologics - for example ruxolitinib therapy (either past or current exposure) - is allowedXx_NEWLINE_xXAny prior systemic anti-cancer immunotherapy treatmentXx_NEWLINE_xXPrior or concurrent systemic anticancer therapy for BC (immunotherapy, hormonotherapy, biologic/targeted therapy, chemotherapy, investigational agents).Xx_NEWLINE_xXParticipant has received anticancer therapy including chemotherapy, immunotherapy, radiation therapy, biologic, herbal therapy, or any investigational therapy within a period of 5 half-lives, prior to the first dose of ABBV-181 or Rovalpituzumab Tesirine.Xx_NEWLINE_xXTreatment with radiation therapy, surgery, chemotherapy, or investigational therapy within four weeks prior to study entryXx_NEWLINE_xXHas had any prior chemotherapy, targeted small molecule therapy, or radiation therapy for the currently diagnosed cancerXx_NEWLINE_xXPrior anti-tumor therapy within 3 weeks of cycle 1 day 1 (anti-tumor therapy defined as, but is not limited to, anti-cancer agents (cytotoxic chemotherapy, immunotherapy, and biologic therapy), radiotherapy, and investigational agents), the “wash-out period”Xx_NEWLINE_xXPatients must have completed previous cancer-related treatments before enrollment. Any concurrent chemotherapy, radiotherapy, immunotherapy, or biologic, or hormonal therapy for cancer excludes the patient (concurrent use of hormones for noncancer-related conditions [eg, insulin for diabetes or hormone replacement therapy] is acceptable). The following intervals between end of the prior treatment and first dose of study drug must be observed:\r\n* Port-a-cath placement: no waiting required\r\n* Minor surgical procedures: >= 7 postoperative days\r\n* Major surgery: >= 4 weeks\r\n* Radiotherapy: >= 4 weeks\r\n* Chemotherapy: >= 4 weeks\r\n* Immunotherapy or investigational anticancer therapy with agents other than monoclonal antibodies (mAbs): >= 4 weeks\r\n* Immunotherapy or investigational anticancer therapy with mAbs: >= 6 weeks\r\n* Immunosuppressive medication: >= 4 weeks with the exceptions of intranasal or inhaled corticosteroids or systemic corticosteroids at physiologic doses not to exceed 10mg/day of prednisone or equivalentXx_NEWLINE_xXConcurrent chemotherapy, hormonal therapy, immunotherapy regimens, or radiation therapy, standard or investigationalXx_NEWLINE_xXIf patient has already started hormonal blockade therapy after radiation as adjuvant therapy, patient is eligible as long as the hormonal therapy was initiated no more than 6 months by the time of screening and can start the study drug within 4 weeks since the completion of screening.Xx_NEWLINE_xXConcurrent treatment with other anti-cancer therapy is not permittedXx_NEWLINE_xXReceipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, radiotherapy or other investigational agent) =< 21 days prior to the first dose of study drug and within 6 weeks for nitrosourea or mitomycin C)Xx_NEWLINE_xXPatients must be at least 4 weeks from previous therapy (chemotherapy, hormonal therapy, and radiation therapy, immunotherapy and monoclonal antibodies, alternative therapy or investigational therapeutic agents); there is no limitation on the amount of prior therapies allowed; patients with ovarian cancer 4 weeks from previous therapy have been found to have normal monocyte function (unpublished)Xx_NEWLINE_xXCurrently receiving other anti-cancer therapy (chemotherapy, radiation therapy, immuno- therapy, biologic therapy, hormonal therapy, surgery, and/or tumour embolization)Xx_NEWLINE_xXPrior radiation therapy, hormonal therapy, biologic therapy, or chemotherapy for prostate cancerXx_NEWLINE_xXHas had any prior chemotherapy, targeted small molecule therapy, or radiation therapy for their current diagnosisXx_NEWLINE_xXChemotherapy, hormonal therapy, radiotherapy (except for brain and extremities), immunotherapy or therapy with monoclonal antibodies or small tyrosine kinase inhibitors within the past 4 weeks prior to treatment with the trial drugXx_NEWLINE_xXReceipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, tyrosine kinase inhibitor, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) =< 30 days prior to the first dose of study drug and within 6 weeks for nitrosourea, mitomycin C or intravesical therapy)Xx_NEWLINE_xXConcurrent or planned use of any other anti-cancer systemic chemotherapy, biological therapy (including hormonal or immune therapy), radiation therapy, or live cancer vaccinesXx_NEWLINE_xXAny concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment; concurrent use of hormones for non-cancer-related conditions (eg, insulin for diabetes and hormone replacement therapy) is acceptableXx_NEWLINE_xXPatients must have not have received any prior therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) for the treatment of stage IV NSCLC; patients may have received prior adjuvant or neoadjuvant chemotherapy or chemotherapy given as part of a curative intent chemoradiotherapy approach for NSCLC, if the last administration of the prior regimens occurred at least 1 year prior to study entryXx_NEWLINE_xXPatients receiving concurrent chemotherapy, radiation therapy, or immunotherapy for AMLXx_NEWLINE_xXCurrently receiving cancer therapy (i.e., chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, and surgery and/or tumor embolization) or any investigational drug within 7 days of cycle 1/day 1, 14 days of cycle 1/day 1 for limited palliative radiation, and/or five half-live of an oral therapy\r\n* Corticosteroid therapy started at least 7 days prior to initiation of treatment (prednisone =< 10 mg daily or equivalent) is allowed as clinically warranted); topical or inhaled corticosteroids are permittedXx_NEWLINE_xXAny major surgery, radiotherapy, chemotherapy, biologic therapy, immunotherapy, experimental therapy within 4 weeks prior to the first dose of the study drugs (except ibrutinib for patients in cohort 3); NOTE: for patients on oral targeted therapies (such as ibrutinib, idelalisib, IPI-145, ACP-196), a wash-out of 3 days from cycle 1 day 1 is acceptableXx_NEWLINE_xXPatients who have received the last administration of an anti-cancer therapy including chemotherapy, immunotherapy, and monoclonal antibodies ? 4 weeks prior to starting study drug, or who have not recovered from the side effects of such therapyXx_NEWLINE_xXAny concurrent chemotherapy, biologic or hormonal therapy for cancer treatment is not permitted within 28 days of registration\r\n* Note: Prior immunotherapy is not permitted\r\n* Note: Concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptableXx_NEWLINE_xXReceipt of any anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) within the last 6 months (mo) (before the first dose of durvalumab)Xx_NEWLINE_xXAny of the following within 3 weeks prior to initiating study treatment\r\n* Systemic biologic therapy\r\n* Monoclonal antibody\r\n* Chemotherapy\r\n* TSEB \r\n* Phototherapy\r\n* Other investigational therapyXx_NEWLINE_xXNO prior chemotherapy, radiation therapy or biologic/targeted therapy for current diagnosis of lung cancerXx_NEWLINE_xXAny concurrent chemotherapy, immunotherapies or biologic or hormonal therapy for cancer treatment; concurrent use of hormones for non-cancer-related conditions (eg, insulin for diabetes and hormone replacement therapy) is acceptable; in addition, local treatment (eg, by local surgery or radiotherapy) of isolated lesions for palliative intent is acceptable beyond the first cycle with prior consultation and in agreement with the principal investigator (PI)Xx_NEWLINE_xXAny concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment; concurrent use of hormones for non-cancer-related conditions (e.g. insulin for diabetes and hormone replacement therapy) is acceptableXx_NEWLINE_xXPART 2 GROUP 1 INCLUSION CRITERIA:  A sufficient interval must have elapsed between the last dose of prior anti-cancer therapy (including cytotoxic and biological therapies) and enrollment in this study, to allow recovery from the acute toxic effects of all prior anti-cancer therapy:\r\n* Myelosuppressive chemotherapy: At least 21 days after the last dose of myelosuppressive chemotherapy\r\n* Hematopoietic growth factors: At least 7 days since the completion of therapy with a growth factor\r\n* Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent\r\n* Immunotherapy: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1; at least 42 days after therapy with a cellular immunotherapy or anti-cancer vaccine\r\n* Radiation therapy: At least 14 days after local palliative radiation therapy (XRT) (small port); >= 6 weeks must have elapsed since treatment with therapeutic doses of metaiodobenzylguanidine (MIBG); >= 6 months must have elapsed from total body irradiation (TBI), craniospinal XRT or 50% radiation of pelvis\r\n* Stem Cell Transplant (SCT): At least 12 weeks after myeloablative therapy with autologous stem cell transplant (timed from start of protocol therapy); subjects must meet adequate bone marrow function definition (see organ function requirements, below) post-myeloablative therapy; patients who received stem cell reinfusion following non-myeloablative therapy are eligible once they meet peripheral blood count criteria below\r\n* Subjects with prior treatment with compound/s with the same mode of action used in one of the treatment groups are eligible if they have not previously received prior treatment with BOTH agents in the combinationXx_NEWLINE_xXPART 2 GROUP 2A INCLUSION CRITERIA: A sufficient interval must have elapsed between the last dose of prior anti-cancer therapy (including cytotoxic and biological therapies) and enrollment in this study, to allow recovery from the acute toxic effects of all prior anti-cancer therapy:\r\n* Myelosuppressive chemotherapy: At least 21 days after the last dose of myelosuppressive chemotherapy\r\n* Hematopoietic growth factors: At least 7 days since the completion of therapy with a growth factor\r\n* Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent\r\n* Immunotherapy: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1; at least 42 days after therapy with a cellular immunotherapy or anti-cancer vaccine\r\n* Radiation therapy: At least 14 days after local palliative XRT (small port); >= 6 weeks must have elapsed since treatment with therapeutic doses of MIBG; >= 6 months must have elapsed from TBI, craniospinal XRT or 50% radiation of pelvis\r\n* SCT: At least 12 weeks after myeloablative therapy with autologous stem cell transplant (timed from start of protocol therapy); subjects must meet adequate bone marrow function definition (see organ function requirements, below) post-myeloablative therapy; patients who received stem cell reinfusion following non-myeloablative therapy are eligible once they meet peripheral blood count criteria below\r\n* Subjects with prior treatment with compound/s with the same mode of action used in one of the treatment groups are eligible if they have not previously received prior treatment with BOTH agents in the combinationXx_NEWLINE_xXPART 2 GROUP 3 INCLUSION CRITERIA: A sufficient interval must have elapsed between the last dose of prior anti-cancer therapy (including cytotoxic and biological therapies) and enrollment in this study, to allow recovery from the acute toxic effects of all prior anti-cancer therapy:\r\n* Myelosuppressive chemotherapy: At least 21 days after the last dose of myelosuppressive chemotherapy\r\n* Hematopoietic growth factors: At least 7 days since the completion of therapy with a growth factor\r\n* Biologic (anti-neoplastic agent): At least 7 days after the last dose of a biologic agent\r\n* Immunotherapy: >= 21 days must have elapsed from infusion of last dose of antibody, and toxicity related to prior antibody therapy must be recovered to grade =< 1; at least 42 days after therapy with a cellular immunotherapy or anti-cancer vaccine\r\n* Radiation therapy: At least 14 days after local palliative XRT (small port); >= 6 weeks must have elapsed since treatment with therapeutic doses of metaiodobenzylguanidine (MIBG); >= 6 months must have elapsed from TBI, craniospinal XRT or 50% radiation of pelvis\r\n* SCT: At least 12 weeks after myeloablative therapy with autologous stem cell transplant (timed from start of protocol therapy); subjects must meet adequate bone marrow function definition (see organ function requirements, below) post-myeloablative therapy; patients who received stem cell reinfusion following non-myeloablative therapy are eligible once they meet peripheral blood count criteria below\r\n* Subjects with prior treatment with compound/s with the same mode of action used in one of the treatment groups are eligible if they have not previously received prior treatment with BOTH agents in the combinationXx_NEWLINE_xXPrior radiation therapy, immunotherapy, chemotherapy or other investigational therapy given for prostate cancerXx_NEWLINE_xXPHASE I: A minimum of 2 weeks will be required from any prior therapy, including chemotherapy, immunotherapy and/or radiation; in addition, recovery to grade =< 1 from all reversible toxicities related to prior therapy is required at study entryXx_NEWLINE_xXProgression during or after first line chemotherapy or chemoradiotherapy; prior maintenance therapy, targeted therapy, and immunotherapy are allowed; prior use of rovalpituzumab is allowed; immunotherapy or targeted therapy will not be considered as second line therapyXx_NEWLINE_xXBefore study therapy, a minimum of 21 days must have elapsed since any prior chemotherapy and 2 weeks from the last dose of prior targeted or immunotherapyXx_NEWLINE_xXMajor surgery, radiotherapy, chemotherapy, biologic therapy, immunotherapy, investigational therapy within 3 weeks prior to the first dose of the study drugsXx_NEWLINE_xXAny concurrent chemotherapy, biologic, or hormonal therapy for cancer treatment, concurrent use of hormonal therapy for non–cancer-related conditions (e.g., hormone replacement therapy) is acceptableXx_NEWLINE_xXHave received 0-2 lines of cytotoxic chemotherapy for metastatic breast cancer; prior endocrine therapy and/or targeted therapy is allowedXx_NEWLINE_xXChemotherapy (including oral agents and targeted agents) or immunotherapy given within 14 days of SRS; hormonal therapy is permitted; for Her2+ breast cancer patients, anti-Her2 therapy cannot be given within 14 days of SRS; patients who are scheduled to receive trastuzumab emtansine after SRS cannot be enrolledXx_NEWLINE_xXPatients may not be receiving any other investigational agents, or concurrent biological therapy, chemotherapy, or radiation therapyXx_NEWLINE_xXIs currently participating and receiving study therapy or concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment at the time of administration of first dose of trial treatment; continuation of hormone replacement therapy is permitted; stable regimens of hormonal therapy i.e. for prostate cancer (e.g. leuprolide, a gonadotrophin releasing hormone [GnRH] agonist), ovarian, or breast cancer are not exclusionaryXx_NEWLINE_xXPatients receiving cytotoxic therapy, radiation therapy, immunotherapy or non-topical steroids for HM within four (4) weeks of enrollment, excluding tyrosine kinase inhibitors in patients with CML.Xx_NEWLINE_xXNo prior chemotherapy, targeted therapy, or immunotherapy for mesotheliomaXx_NEWLINE_xXHas received any prior anticancer therapy for mesothelioma (no prior chemotherapy, immunotherapy, or targeted therapy)Xx_NEWLINE_xXHas had any major surgery, extensive radiotherapy, or anti-cancer therapy (e.g., chemotherapy with delayed toxicity, biologic therapy, or immunotherapy) within 21 days prior to enrolment and/or daily or weekly chemotherapy without the potential for delayed toxicity within 14 days prior to enrolment. Prolonged immobilization must have resolved prior to enrolment.Xx_NEWLINE_xXReceipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) =< 14 days prior to the first dose of study drug (=< 7 days or four half-lives, whichever is longer, prior to the first dose of study drug for subjects who have received prior tyrosine kinase inhibitors [TKIs] [e.g., erlotinib, gefitinib and crizotinib] and within 6 weeks for nitrosourea or mitomycin C)Xx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation)Xx_NEWLINE_xXOther concurrent chemotherapy, radiotherapy, or any ancillary therapy considered investigational; Note: bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatmentXx_NEWLINE_xXFewer than 28 days from prior anticancer therapy including chemotherapy, hormonal, investigational, and/or biological therapies and irradiation except for prostate cancer hormonal therapy, and treatment with MVT-5873 and MVT-2163.Xx_NEWLINE_xXPatients who have had chemotherapy, immunotherapy or any targeted therapy within 7 days prior to anticipated SRS treatment date or those planning for systemic therapy within 7 days following the protocol treatmentXx_NEWLINE_xXConcurrent treatment with any anticancer agent, including chemotherapy, immunotherapy, or biologic therapy; in breast cancer patients, concurrent use of hormonal therapy (but not trastuzumab) is acceptable provided hormonal therapy was initiated more than 30 days prior to treatment on this studyXx_NEWLINE_xXExcluded therapies and medications for cancer\r\n* Anticancer chemotherapy or immunotherapy during the study or within 4 weeks of study enrollment; subjects must have recovered from the toxic effects of the previous anti-cancer chemotherapy or immunotherapy (with the exception of alopecia); anti-cancer therapy is defined as any agent or combination of agents with clinically proven anti-tumor activity administered by any route with the purpose of affecting the malignancy, either directly or indirectly, including palliative and therapeutic endpoints; however, subjects with prostate cancer who are receiving depot luteinizing hormone-releasing hormone (LHRH) agonist therapy may continue on this treatment\r\n* Hormonal therapy during the study or within 2 weeks of first study enrollment\r\n* Radiotherapy to target lesions during study or within 4 weeks of first study treatment\r\n* An irradiated lesion is considered evaluable only if it has shown enlargement since the completion of last radiation\r\n* Bone marrow transplant or stem cell rescue\r\n* Bisphosphonate therapy during the first 2 cycles of treatment\r\n* Granulocyte colony stimulating factor (G-CSF) and other hematopoietic growth factors may be used in the management of acute toxicity such as febrile neutropenia when clinically indicated or at the discretion of the principal investigator; however they may not be substituted for a required dose reduction; erythropoietins are not permitted\r\n* Investigational drug therapy outside of this trial during or within 4 weeks of first study treatmentXx_NEWLINE_xXMajor surgery, radiotherapy, chemotherapy, biologic therapy, immunotherapy, experimental therapy within 3 weeks prior to the first dose of the study drugs and/or monoclonal antibody =< 6 weeks prior to first administration of study treatmentXx_NEWLINE_xXPatients receiving concurrent anti-cancer treatment (chemotherapy, investigational agents, immunotherapy, endocrine therapy, or Optune®…)Xx_NEWLINE_xXPrior chemotherapy provided patients have been off previous anti-cancer therapy for at least 21 days and recovered from all treatment related toxicityXx_NEWLINE_xXPrior anti-cancer therapy (e.g., biologic or other targeted therapy, chemotherapy) within 28 days (6 weeks for nitrosoureas or mitomycin C, and 14 days for hormonal therapy or kinase inhibitors) before the first dose of study treatment on Study Day 1 of Period A.Xx_NEWLINE_xXPatients who concurrently use hormonal therapy and/or concurrent radiation therapyXx_NEWLINE_xXReceipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) 30 days prior to the first dose of study drug 30 days prior to the first dose of study drug for subjects who have received prior tyrosine kinase inhibitors (TKIs) (e.g., erlotinib, gefitinib and crizotinib) and within 6 weeks for nitrosourea or mitomycin CXx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy.Xx_NEWLINE_xXNo prior receipt of systemic treatment (chemotherapy, targeted therapy, or immunotherapy) for the lesion under consideration of treatmentXx_NEWLINE_xXPHASE I: Any other therapy directed at treating the cancer including chemotherapy, biologic/targeted agents, and immunologic agents, must be discontinued at least three weeks prior to enrollmentXx_NEWLINE_xXPHASE II: Any other therapy directed at treating the cancer including chemotherapy, biologic/targeted agents, and immunologic agents, must be discontinued at least three weeks prior to enrollmentXx_NEWLINE_xX4 weeks from prior chemotherapy ( 6 weeks for mitomycin C and nitrosourea) , immunotherapy, investigational anti-cancer therapy, radiation therapy; and have recovered from prior toxicitiesXx_NEWLINE_xXAny major surgery, radiotherapy, chemotherapy, biologic therapy, immunotherapy, experimental therapy within 2 weeks prior to the first dose of the study drugsXx_NEWLINE_xXNo prior treatment for primary invasive adenocarcinoma of the breast such as irradiation, chemotherapy, hormonal therapy, immunotherapy, investigational therapy or surgery other than the anthracycline and cyclophosphamide chemotherapy with or without 5-fluorouracil; treatment for ductal carcinoma in situ is allowed, such as surgery, hormonal therapy and radiotherapyXx_NEWLINE_xXAny major surgery, radiotherapy, chemotherapy, biologic therapy, immunotherapy, experimental therapy within 2 weeks prior to the first dose of the study drugsXx_NEWLINE_xXPatients who are receiving concurrent non-protocol anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, hormonal therapy, targeted therapy, biologic therapy, or tumor embolization) are to be excludedXx_NEWLINE_xXChemotherapy, immunotherapy, hormonal therapy, biologic therapy, or any other anticancer therapy or investigational medicinal product (IMP) within 28 days of first trial drug intake for Phase Ia subjects, and any prior therapy for Phase Ib subjects. For subjects with rapidly growing tumors localized in the head and neck region or thorax where the treating physician cannot wait for 28 days, inclusion may take place if there is no residual toxicity from previous treatment (maximum CTCAE Grade 1)Xx_NEWLINE_xXConcurrent anticancer therapy (eg, chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or hormonal therapy).Xx_NEWLINE_xXReceiving concurrent anti-cancer treatment (excluding radiation therapy), either approved or investigationalXx_NEWLINE_xXHave received biologic therapy, including immunotherapy, < 28 days prior to C1D1;Xx_NEWLINE_xXHas been treated with anti-cancer therapy or thoracic radiation therapy within 14 daysXx_NEWLINE_xXReceived prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to starting study treatment or not recovered from adverse events due to a previously administered agentXx_NEWLINE_xXPatient has fully recovered from the acute toxic effects of chemotherapy, immunotherapy, or radiation therapy prior to entering this study:\r\n* Myelosuppressive chemotherapy: patient has not received myelosuppressive chemotherapy within 3 weeks of enrollment onto this study (4 and 6 weeks if prior temozolomide and nitrosourea, respectively)\r\n* Hematopoietic growth factors: at least 7 days must have elapsed since the completion of therapy with a growth factor; at least 14 days must have elapsed after receiving pegfilgrastim\r\n* Biologic (anti-neoplastic agent): at least 7 days must have elapsed since completion of therapy with a biologic agent; for agents that have known adverse events occurring beyond 7 days after administration, this period prior to enrollment must be extended beyond the time during which adverse events are known to occur\r\n* Monoclonal antibodies: at least three half-lives must have elapsed since prior therapy that included a monoclonal antibody\r\n* Radiation therapy: at least 3 months must have elapsed since any previous irradiation; unless measurable disease progression occurs at a site separate from the irradiated area and the patient has recovered from toxicities associated with radiation therapyXx_NEWLINE_xXSubject has received anticancer therapy including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within a period of 21 days or herbal therapy within 7 days prior to the first dose of ABBV-399.Xx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study and meet all of the following criteria:\r\n* Myelosuppressive chemotherapy: 14 days must have elapsed since the completion of myelosuppressive therapy; individuals may have received any of the following medications within 14 days without a “wash-out” period:\r\n** Standard maintenance therapy (vincristine, mercaptopurine [6MP], corticosteroids, low dose methotrexate)\r\n** Hydroxyurea\r\n** Intrathecal chemotherapy with methotrexate, hydrocortisone and/or cytarabine\r\n* Radiation therapy (XRT):\r\n** Total body irradiation (TBI) or craniospinal radiation therapy: must have been completed more than 90 days from study entry\r\n** Palliative XRT: XRT for chloromas does not require a washout period\r\n* Biologic (anti-neoplastic agent): at least 7 days after the last dose of a biologic agent; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur; the duration of this interval must be discussed with the study chair\r\n* Immunotherapy: at least 6 weeks after the completion of any type of immunotherapy, e.g. tumor vaccines and chimeric antigen receptor T-cells\r\n* Monoclonal antibodies: at least 3 half-lives of the antibody after the last dose of a monoclonal antibodyXx_NEWLINE_xXPatients will be excluded if there is a plan to administer non-protocol chemotherapy, radiation therapy, or immunotherapy during the study periodXx_NEWLINE_xXAll patients must have completed any prior chemotherapy, targeted therapy, radiotherapy (unless palliative doses which must be discussed with study principal investigator), surgery, anti-angiogenic therapy or interferon >= 28 days before study entryXx_NEWLINE_xXNo prior chemotherapy in the recurrent setting; prior hormonal therapy is permitted; concomitant anti-neoplastic anti-hormonal therapy (including tamoxifen, aromatase inhibitors etc.) is not allowed for patients participating in study treatment; low-dose (physiologic) estrogen hormone-replacement therapy (HRT) may be givenXx_NEWLINE_xXLiver tumor-directed therapy, hepatic surgery, antibody-based therapy, or immunotherapy must not have been performed < 28 days, chemotherapy < 21 days, and targeted small molecule therapy or hormonal therapy < 14 days prior to enrollment.Xx_NEWLINE_xXPrior therapy: >= 3 weeks should have elapsed since last cytotoxic therapy, immunotherapy or radiation therapy; more than one week should have elapsed since major surgeryXx_NEWLINE_xXPatients previously treated with immunotherapy, targeted therapy, or no therapy (treatment naive) will be eligibleXx_NEWLINE_xXPatients must not have received any anti-cancer therapy (cytotoxic chemotherapy, targeted therapy or radiation) within the past 28 days prior to initiation of study therapyXx_NEWLINE_xXChemotherapy, immunotherapy, biologically targeted therapy, other investigational agent, or radiation therapy within 3 weeks of initiation of enzalutamide therapy; for patients with objectively progressive disease on a Bruton tyrosine kinase (BTK)-targeting agent whom in the opinion of the investigator would not tolerate a 21 day washout period, a > 5 half-lives washout period will be allowedXx_NEWLINE_xXAll therapy (except hormonal therapy) directed at the malignant tumor must be discontinued at least 21 days prior to registrationXx_NEWLINE_xXPHASE I STUDY ELIGIBILITY CRITERIA:\r\nAny concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment; concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable; NOTE: local treatment of isolated lesions for palliative intent is acceptable (e.g., by local surgery or radiotherapy)Xx_NEWLINE_xXPHASE II STUDY COHORT 1 OVARIAN CANCER ELIGIBILITY CRITERIA (MEDI+O, MEDI+C AND MEDI+O+C):\r\nAny concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment; concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable; NOTE: Local treatment of isolated lesions for palliative intent is acceptable (e.g., by local surgery or radiotherapy)Xx_NEWLINE_xXPHASE II STUDY COHORT 5 TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nAny concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment; concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable; NOTE: Local treatment of isolated lesions for palliative intent is acceptable (e.g., by local surgery or radiotherapy)Xx_NEWLINE_xXPHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nConcurrent enrollment in another clinical study, unless it is an observational non-interventional clinical study or the follow-up of an interventional study; any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment; concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptable; NOTE: Local treatment of isolated lesions for palliative intent is acceptable (e.g., by local surgery or radiotherapy)Xx_NEWLINE_xXConcurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, hormonal therapy, biologic therapy) other than the ones specified in the protocol; patients must have discontinued the above cancer therapies for 1 week prior to the first dose of study medication; any investigational drugs should be discontinued 2 weeks prior to the first dose of study medication and radiotherapy must have been completed >= 2 weeks prior to initiation of study drug (cycle 1, day 1)Xx_NEWLINE_xXPrevious treatment: prior systemic anti-cancer treatment consisting of chemotherapy, immunotherapy, or targeted therapy are allowed provided therapy completed at least 1 year prior to enrollment\r\n* No prior talimogene laherparepvec or tumor vaccines allowed\r\n* No prior radiation to the same tumor bed allowedXx_NEWLINE_xXNo prior therapy for pancreatic cancer, including chemotherapy, radiation therapy, definitive surgery or investigational therapyXx_NEWLINE_xXAny major surgery, radiotherapy, cytotoxic chemotherapy, biologic therapy, immunotherapy, immunomodulatory drugs, experimental therapy within 4 weeks prior to the first dose of the study drugs; Note: prior therapy with anti cluster of differentiation (CD)20 monoclonal antibody, anti CD52 monoclonal antibody, and lenalidomide are allowed; for oral targeted therapies (such as idelalisib, venetoclax), a washout of 3 days is allowedXx_NEWLINE_xXAny anti-cancer therapy within the past 21 days of the first day of treatmentXx_NEWLINE_xXPrior systemic anti-cancer treatment (chemotherapy, immunotherapy, biologic therapy, vaccine therapy or investigational treatment within 3 weeks preceding first dose of study treatment, or chemotherapy without delayed toxicity within 2 weeks preceding first dose of study treatmentXx_NEWLINE_xXPrior systemic treatments for metastatic disease are permitted but may not be ongoing, including targeted therapies, biologic response modifiers, chemotherapy, hormonal therapy, or investigational therapyXx_NEWLINE_xXPatients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy; may have received an experimental agent prior to enrolling in the trialXx_NEWLINE_xXChemotherapy (including hormonal therapy) within the past 5 years from date of registrationXx_NEWLINE_xXMust be at least 7 days since last chemotherapy or biologic therapy administered; for patients previously enrolled on this trial who had a usable T cell product generated but removed prior to receiving T cell therapy and are re-enrolling on the trial, the time from chemotherapy agent or biologic agent is not restrictedXx_NEWLINE_xXConcurrent treatment with other anticancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, radiotherapy, chemo-embolization, targeted therapy, or an investigational agentXx_NEWLINE_xXNo chemotherapy, immunotherapy, hormonal therapy, or biological therapy for cancer, radiotherapy, or surgical procedures (except for minor surgical procedures) within four weeks before beginning treatment with SB-485232 (six weeks for nitrosoureas and mitomycin C); subjects must have recovered at least to grade 2 from toxicities (incurred as a result of previous therapy) sufficiently to be entered into a Phase I studyXx_NEWLINE_xXConcurrent treatment with other investigational drugs or anti-cancer therapy.Xx_NEWLINE_xXTherapy with myelosuppressive chemotherapy or biologic therapy < 21 days prior to registration unless the patient has recovered from the nadir of the previous treatment to a level that meets the inclusion eligibility criteria of this protocolXx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation)Xx_NEWLINE_xXCurrently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy) or investigational anti-cancer drugXx_NEWLINE_xXPatients who have received the last administration of an anti-cancer therapy including chemotherapy, immunotherapy, hormonal therapy and monoclonal antibodies (but excluding nitrosourea, mitomycin-C, targeted therapy and radiation) =< 4 weeks prior to starting study drugXx_NEWLINE_xXAny concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment; NOTE: local treatment of isolated lesions, excluding target lesions, for palliative intent is acceptable (e.g., by local ablation, surgery or radiotherapy)Xx_NEWLINE_xXPrevious chemotherapy, immunotherapy, biologically targeted therapy, other investigational agent, or radiation therapy within 3 weeks of initiation of ibrutinib therapy or radio-immunotherapy within 12 weeks of initiation of ibrutinib therapyXx_NEWLINE_xXReceived any of the following for treatment of this cancer (except for the neoadjuvant endocrine therapy specified within this protocol):\r\n* Surgery\r\n* Radiation therapy\r\n* Chemotherapy\r\n* Biotherapy\r\n* Hormonal therapy\r\n* Investigational agentXx_NEWLINE_xXRecovery from effects of any recent surgery, chemotherapy and/or radiation:\r\n* No evidence of active infection requiring antibiotic therapy\r\n* Hormonal therapy being utilized, as an anti-neoplastic treatment must be discontinued at least one week prior to study entry; hormonal replacement therapy for symptom management is allowed\r\n* Any prior therapy directed at the malignancy including biologic or immunologic agents, must have be discontinued at least three weeks prior to study entryXx_NEWLINE_xXTreatment with any of the following anti-cancer therapies:\r\n* Radiation therapy, surgery, or tumor embolization within 14 days prior to the first dose of pazopanib OR\r\n* Chemotherapy, immunotherapy, investigational therapy, or hormonal therapy within 14 days prior to the first dose of pazopanibXx_NEWLINE_xXAny prior treatment with radiation therapy, chemotherapy, biotherapy, or hormone therapy for the currently diagnosed breast cancer prior to study enrollmentXx_NEWLINE_xXPatients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy or radiotherapy) concurrently or within 2 weeks of starting study treatment with sonidegibXx_NEWLINE_xXCurrent concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocolXx_NEWLINE_xXPHASE I and II -- Administration of any antineoplastic therapy within at least 4 weeks (cytotoxic chemotherapy) or 2 weeks (biological and targeted therapy; hypomethylating agents are considered to be biological therapy) of that therapy of the first MEK 162/MEK 162 dose; except the use of hydroxyurea which can be administered up to 5 g/day up to 24 hours before the initiation of the study drugXx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation)Xx_NEWLINE_xXPrior therapy for melanoma that may include surgery, radiation therapy, immunotherapy including interleukins and interferon, and/or ?2 different regiments of systemic chemotherapy, targeted therapy, or other experimental systemic therapies. Prior treatment with immune checkpoint inhibitors is not allowed.Xx_NEWLINE_xXChemotherapy (including hormonal therapy) within the past 5 years from date of registrationXx_NEWLINE_xXPatients who have had any prior treatment for CLL, including chemotherapy, corticosteroids, biologic therapy, or immunotherapy are NOT eligible for participationXx_NEWLINE_xXPatient who has had chemotherapy, radiation, hormonal, or biological cancer therapy < 4 weeks prior to the first dose of study drugXx_NEWLINE_xXPatients must not have any significant toxicity associated with prior surgery, radiation therapy, chemotherapy, or immunotherapy, per principal investigator (PI) discretionXx_NEWLINE_xXPatients previously treated with immunotherapy, targeted therapy, or no therapy (treatment naive) will be eligible (Turnstile I)Xx_NEWLINE_xXHormonal therapy, radiation therapy, biologic therapy, chemotherapy or other systemic antitumor therapy for pancreatic cancer within 14 days prior to Cycle 1 Day 1Xx_NEWLINE_xXDiagnosis of stage 0-III breast cancer within 12 years prior to enrollment; all indicated surgery, chemotherapy, and/or radiation therapy must have been completed at least 12 weeks prior to enrollment; concomitant endocrine therapy and targeted therapies such as palbociclib, pertuzumab, and trastuzumab are permittedXx_NEWLINE_xXPrevious treatment with surgery, radiation, chemotherapy, immunotherapy or any targeted agents are allowed provided that: \r\n* Chemotherapy was administered > 28 days before the start of HD IL-2\r\n* Surgery, radiation, immunotherapy or any targeted agents was administered > 14 days before the start of HD IL-2Xx_NEWLINE_xXConcomitant use of any anti-cancer therapy or radiation therapyXx_NEWLINE_xXHormonal therapy within 1 weekXx_NEWLINE_xXAny prior therapy for the treatment of pancreatic malignancy (including chemotherapy, immunotherapy, vaccines, monoclonal antibodies, major surgery, or irradiation, whether conventional or investigational).Xx_NEWLINE_xXPatients taking any other concurrent approved or investigational anti-cancer therapy (e.g. chemotherapy, immunotherapy, targeted or biologic therapy)Xx_NEWLINE_xXPatients must have had no chemotherapy, biologic therapy, or radiation therapy for their malignancy for at least 30 days prior to treatment; patients may have received localized radiation therapy to non-target lesions provided that the radiotherapy is completed 14 days prior to commencing therapy, and the patient has recovered from any toxicity; at least 3 half-lives must have elapsed since monoclonal antibody treatment; at least six weeks must have elapsed between mitomycin C or nitrosourea treatmentXx_NEWLINE_xXLast dose of chemotherapy, immunotherapy, biologic therapy, or investigational therapy, was less than 14 days prior to protocol therapy (radiation and veliparib)Xx_NEWLINE_xXFor purposes of this protocol, anti-tumor treatment may be defined as, but is not limited to, anti-cancer agents (cytotoxic chemotherapy, immunotherapy, biologic therapy), radiotherapy, and investigational agents; an investigational agent is any drug or therapy not currently approved for use in humans\r\n* Anti-cancer agents: anti-cancer agents are not permitted within 21 days prior to start of POPI; there are no limitations on the type or number of prior regimens; hormonal therapy and trastuzumab are permitted during POPI\r\n* Radiation: prior treatment with breast irradiation is not allowed \r\n* Surgery: incident breast biopsies only permitted prior to POPI to confirm residual disease after NACXx_NEWLINE_xXPatients who have received systemic cytotoxic chemotherapy or approved oral targeted therapy or immunotherapy for 2 weeks, or other investigational agents for 3 weeks (4 half-lives for any oral targeted agents), or radiotherapy to a non-brain site for 2 weeks before initiation of IPdR therapy; patients who have recovered from serious (Common Terminology Criteria for Adverse Events [CTCAE] grade 3 or more higher) to grade 1 or less adverse events from the previous therapies are eligible; prior/current/future hormonal therapy and/or bisphosphonates are permitted with no minimum interval to initiation of study therapy; if indicated, patients can receive palliative radiation therapy to a non-brain site concurrent or immediately post-study treatment with no minimum interval to initiation of study therapyXx_NEWLINE_xXPrior radiotherapy, surgery, chemotherapy, or hormonal therapy for prostate cancerXx_NEWLINE_xXOther concurrent chemotherapy, radiotherapy, or any ancillary therapy considered investigational\r\n* NOTE: bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatmentXx_NEWLINE_xXRequire concomitant chemotherapy, radiation therapy, or immunotherapy. Hydroxyurea is allowed up to the evening before starting (but not within 12 hours) of starting treatment on either arm.Xx_NEWLINE_xXPatients must have completed any previous cancer-related treatments before enrolment. Any concurrent chemotherapy [Chemotherapy washout within 21 days or 5 half-lives (whichever is shorter) from enrolment], radiotherapy, immunotherapy, or biologic, or hormonal therapy for cancer excludes the patient (concurrent use of hormones for noncancer-related conditions [eg, insulin for diabetes and hormone replacement therapy] is acceptable),Xx_NEWLINE_xXOther anti-cancer or investigational therapy while patients are on study therapyXx_NEWLINE_xXPatients must be at least 3 weeks past any prior surgery, cytotoxic, chemotherapy, other immunotherapy, hormonal therapy, or radiation therapy; patients having been treated with monoclonal antibodies may enter the trial after a specified period of time (2 times the mean half-life of the agent); patients must have recovered from any toxicity of prior therapy prior to enrolling on study except for neuropathy where patients need to recover to less than grade 2Xx_NEWLINE_xXPrior therapy: at least 4 weeks should have elapsed since any biologic therapy, or immunotherapy; three weeks should have elapsed since last dose of chemotherapy or radiotherapyXx_NEWLINE_xXRadiation therapy, hormonal therapy, biologic therapy or chemotherapy for cancer within the 28 days prior to day 1 of study drug\r\n* For the NSCLC expanded cohort only: palliative radiation therapy =<14 days of day 1 of study drugXx_NEWLINE_xXChemotherapy, radiation therapy, or biologic therapy (except trastuzumab) within 28 days prior to initiating treatment on study; endocrine therapy and supportive therapy with bisphosphonates will be allowedXx_NEWLINE_xXHas had prior chemotherapy, radiation therapy, or immunotherapy for the diagnosis of iBCLXx_NEWLINE_xXPatient has received anticancer chemotherapy, TKIs, biologics, immunotherapy, radiotherapy, or investigational treatment within 15 days. (There is no washout for hormonal therapy for breast cancer).Xx_NEWLINE_xXOther concurrent chemotherapy or any ancillary therapy considered investigational\r\n* NOTE: Bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatmentXx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, radiotherapy or investigational therapy.Xx_NEWLINE_xXPlans for the patient to receive other concomitant antineoplastic therapy (including standard fractionated radiotherapy, chemotherapy, biological therapy, vaccine therapy, and surgery) while on this protocol except at disease progressionXx_NEWLINE_xXChemotherapy, targeted therapy, biologic or hormonal agents within 3 weeks prior to entering the studyXx_NEWLINE_xXAny major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 30 days of enrollment and/or daily or weekly chemotherapy without the potential for delayed toxicity within 14 days of enrollmentXx_NEWLINE_xXSubjects must have completed chemotherapy, targeted therapy, investigational therapy, other immunotherapy, prior radiotherapy, or major surgery (requiring general anesthesia) at least 28 days before administration of the first dose of study drug(s). Subjects undergoing minor surgical procedures and biopsies that do not require general anesthesia may begin receiving study therapy if sufficiently recovered as determined by the treating investigator. Clinically significant toxicity experienced during any prior therapy must be resolved or stabilized before the first dose of study drug(s).Xx_NEWLINE_xXPatients receiving cytotoxic therapy (including endocrine and biological agents), radiation therapy, immunotherapy or non-topical steroids, within three (3) to four (4) weeks of enrollment.Xx_NEWLINE_xXHas received chemotherapy (except hydroxyurea), biological therapy, radiotherapy or investigational therapy within 4 weeks before baseline (C1D1).Xx_NEWLINE_xXTreatment with any of the following anti-cancer therapies: radiation therapy, surgery or tumor embolization, chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy =< 14 days prior to registrationXx_NEWLINE_xXThe patient should be off chemotherapy, biologic therapy and radiation for 28 days.Xx_NEWLINE_xXPrior hormonal therapy, aromatase inhibitor therapy, and immunotherapy allowedXx_NEWLINE_xXAt least 4 weeks and recovery from effects of prior surgery, hormonal therapy, aromatase inhibitor therapy, immunotherapy, radiotherapy, or other therapy with an approved or investigational agentXx_NEWLINE_xXLess than 3 weeks since prior chemotherapy, radiation therapy, or immunotherapy. However, hydroxyurea is permitted up to 24 hours before the study is initiated;Xx_NEWLINE_xXConcurrent anti-cancer therapyXx_NEWLINE_xXPatients must not have received any prior tumor-directed therapy including radiation therapy, chemotherapy (tumor-directed therapy), molecularly targeted agents, or immunotherapy for the treatment of HGG other than surgical interventionXx_NEWLINE_xXParticipant has received anti-cancer therapy (including chemotherapy, immunotherapy, radiotherapy, hormonal, biologic, or any investigational therapy) prior to Study DayXx_NEWLINE_xXNo other anticancer-therapy (chemotherapy, immunotherapy, hormonal anti-cancer therapy, radiotherapy [except for palliative local radiotherapy]), biological therapy or other novel agent is to be permitted while the patient is receiving study medication; patients on luteinizing hormone-releasing hormone (LHRH) analogue treatment for more than 6 months are allowed entry into the study and may continue at the discretion of the investigatorXx_NEWLINE_xXHistory of systemic anti-cancer therapy (e.g., chemotherapy, targeted therapy) for metastatic breast cancer (MBC) with the exception of administration of trastuzumab or lapatinib concurrently with radiation therapy for brain metastases; toxicities related to lapatinib should be =< grade 1, per the CTCAE version (v)5.0 and must have been completed at least 2 weeks prior to randomizationXx_NEWLINE_xXLiver tumor-directed therapy, hepatic surgery, antibody-based therapy, or immunotherapy must not have been performed < 28 days, chemotherapy < 21 days, and targeted small molecule therapy or hormonal therapy < 14 days prior to enrollment. No radiation to tumor sites during the last 4 weeks.Xx_NEWLINE_xXIf they are undergoing or have undergone in the past 4 weeks (28 days) any other therapy for their cancer, including radiation therapy and chemotherapyXx_NEWLINE_xXPrevious systemic therapy for stage IV NSCLC, including chemotherapy, radiation therapy or non-cytotoxic investigational agents.Xx_NEWLINE_xXPatients must have received previous systemic therapy to include: a regimen of chemotherapy, immunotherapy including anti-PDL or anti-PD-L1 therapies, combined chemotherapy and immunotherapy, provided treatment was discontinued >= 2 weeks prior to initiation of treatment on the present protocolXx_NEWLINE_xXSubject is receiving concurrent chemotherapy or biologic or hormonal therapy for cancer treatment; Note: Concurrent use of hormones for noncancer-related conditions (e.g., insulin for diabetes) is acceptableXx_NEWLINE_xXPrior systemic anti-cancer treatment (e.g. chemotherapy, tyrosine kinase inhibitors, immunotherapy, or investigational agents)(except for hydroxyurea and/or leukapheresis)Xx_NEWLINE_xXPrevious chemotherapy or hormonal therapy for treatment of ovarian cancer.Xx_NEWLINE_xXAny concurrent chemotherapy, investigational product (IP), biologic, or hormonal therapy for cancer treatment; receipt of any investigational or approved anticancer therapy (chemotherapy, targeted therapy, biologic therapy, monoclonal antibodies, etc.) within 21 days or 5 half lives, whichever is shorter, prior to the first dose of MEDI0457; concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study.Xx_NEWLINE_xXAny prior immunotherapy or vaccine therapyXx_NEWLINE_xXAny anti-cancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within 2 weeks prior to initiation of study treatment, with the following exceptions:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Herbal therapy > 1 week before week 1, day 1 (herbal therapy intended as anti-cancer therapy must be discontinued at least 1 week before week 1, day 1)Xx_NEWLINE_xXReceipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) within 28 days prior to the first dose of study drug and within 6 weeks for nitrosourea or mitomycin CXx_NEWLINE_xXAny major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 21 days prior to randomization and/or daily or weekly chemotherapy without the potential for delayed toxicity within 14 days prior to randomizationXx_NEWLINE_xXNo prior systemic chemotherapy, systemic biologic/molecular targeted therapy or radiation treatment for head and neck cancerXx_NEWLINE_xXPrior systemic chemotherapy, molecularly targeted therapy, or radiation therapy for the current OPSCC diagnosisXx_NEWLINE_xXExcluded therapies and medications, previous and concomitant\r\n* Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than study treatment (regorafenib)\r\n* Prior use of regorafenib\r\n* Concurrent use of chemotherapy, radiotherapy or another investigational drug or device therapy (i.e., outside of study treatment) during, or within 4 weeks of trial entry (signing of the informed consent form)\r\n* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication\r\n* Use of any herbal remedy (e.g. St. John’s wort [Hypericum perforatum])Xx_NEWLINE_xXUse of concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocolXx_NEWLINE_xXHas any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for invasive malignancy within 2 years. Concurrent use of hormones for non-cancer-related conditions (eg, insulin for diabetes and hormone replacement therapy) is acceptable.Xx_NEWLINE_xXPart 2 patients must not have received prior radiation therapy, chemotherapy, immunotherapy or therapy with biologic agent (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, tumor infiltrating lymphocytes [TIL], lymphokine-activated killer [LAK] or gene therapy), or hormonal therapy for their brain tumor; glucocorticoid therapy is allowedXx_NEWLINE_xXPrior anti-cancer therapy (chemotherapy, targeted agents, radiotherapy, and immunotherapy) within 14 days except for alkylating agents (e.g., melphalan) within 28 days.Xx_NEWLINE_xXPatient is concurrently using other anti-cancer therapy. All anti-cancer therapy must be discontinued prior to day one of study treatment.Xx_NEWLINE_xXTreatment with any approved anti-cancer therapy, including chemotherapy, immunotherapy, radiopharmaceutical or hormonal therapy (with the exception of abiraterone), within 4 weeks prior to initiation of study treatmentXx_NEWLINE_xXNaïve to prior chemotherapy or immunotherapy (i.e., this is a first-line systemic therapy study).Xx_NEWLINE_xXTreatment with any systemic anti-neoplastic therapy, or investigational therapy within the 3 weeks prior to the initiation of study drug.Xx_NEWLINE_xXAt the time of enrollment, subjects may not have had any prior systemic therapy for breast cancer, including chemotherapy, targeted biologic therapy, or greater than 3 months of hormonal therapy; similarly, chemotherapy or biologic therapy must not be part of the subsequent treatment planXx_NEWLINE_xXAntineoplastic therapy (e.g. chemotherapy or targeted therapy) for other invasive cancer within 5 years before randomization; (for the purposes of this study, hormonal therapy is not considered chemotherapy)Xx_NEWLINE_xXPrior immunotherapyXx_NEWLINE_xXPrior systemic therapy, including cytotoxic chemotherapy, biologic/targeted therapy, or immune therapy for the study cancerXx_NEWLINE_xXPatients must not have received prior radiation therapy (RT), chemotherapy, immunotherapy or therapy with a biologic agent (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, tumor-infiltrating lymphocytes, lymphokine-activated killer cells, or gene therapy), or hormonal therapy for their brain tumor; corticosteroid therapy is allowedXx_NEWLINE_xXAny cytotoxic or biologic therapy less than 2 weeks prior to initiation of therapy.Xx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy\r\n* Myelosuppressive chemotherapy: must not have received chemotherapy within 2 weeks of enrollment and within 2 week of starting protocol therapy\r\n* Hematopoietic growth factors: at least 7 days since the last dose of growth factor therapy for both enrollment on study and for commencement of protocol therapy\r\n* Immunotherapy: patients may not have received immunotherapy within 3 weeks of enrollment and within 6 weeks of commencing protocol therapyXx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA] approved indication and in the context of a research investigation)Xx_NEWLINE_xXARM A: Other concurrent chemotherapy, immunotherapy, radiotherapy, or investigational therapyXx_NEWLINE_xXARM B: Other concurrent chemotherapy, immunotherapy, radiotherapy, or investigational therapyXx_NEWLINE_xXConcurrent anti-cancer therapy (chemotherapy, radiotherapy, immunotherapy, hormonal therapy, or any other biologic therapy)Xx_NEWLINE_xXPrior anti-cancer therapy (chemotherapy, targeted agents, radiotherapy, and immunotherapy) within the prior 21 days except for alkylating agents (e.g. melphalan) within the prior 28 daysXx_NEWLINE_xXPatients must not have had chemotherapy, molecular therapy with erlotinib, radiation therapy, or experimental biological or molecular therapy for at least 4 weeks prior to starting study medication; patients who received FOLFIRINOX must be 6 weeks from the last administration of therapy; patients must have recovered from any acute toxicity related to prior therapy or surgery, to a grade 1 or less unless specifiedXx_NEWLINE_xXReceipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) =< 28 days prior to the first dose of study drug (=< 28 days prior to the first dose of study drug for subjects who have received prior tyrosine kinase inhibitors [TKIs] [e.g., erlotinib, gefitinib and crizotinib] and within 6 weeks for nitrosourea or mitomycin C); (if sufficient wash-out time has not occurred due to the schedule or pharmacokinetics [PK] properties of an agent, a longer wash-out period may be required)Xx_NEWLINE_xXPatients must have had no chemotherapy, biologic therapy, or radiation therapy for their malignancy for at least 30 days prior to treatment; patients may have received localized radiation therapy to non-target lesions provided that the radiotherapy is completed 14 days prior to commencing therapy, and the patient has recovered from any toxicity; at least 3 half-lives must have elapsed since monoclonal antibody treatment; at least six weeks must have elapsed between mitomycin C or nitrosourea treatmentXx_NEWLINE_xXPatients may have received prior hormonal therapy for treatment of endometrial carcinoma; all hormonal therapy must be discontinued at least 4 weeks prior to registrationXx_NEWLINE_xXPatients may have received prior therapy (including chemotherapy, biologic/targeted therapy and immunotherapy) for treatment of endometrial cancer; all therapy must be discontinued at least 4 weeks prior to registration; any investigational agent must be discontinued at least 30 days prior to registrationXx_NEWLINE_xXOther concurrent chemotherapy, radiotherapy, or any ancillary therapy considered investigational; NOTE: bisphosphonates are allowed while on protocol treatmentXx_NEWLINE_xXPrior systemic anti-cancer therapy (chemotherapy with delayed toxicity, extensive radiation therapy, immunotherapy, biologic therapy, or vaccine therapy) within the last 3 weeks; chemotherapy regimens without delayed toxicity within the last 2 weeks preceding the first dose of study treatmentXx_NEWLINE_xXTherapy with myelosuppressive chemotherapy or biologic therapy < 21 days prior to registration; NOTE: patients who have recovered from cytopenia related to previous treatment and meet criteria of this protocol will be eligibleXx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation)Xx_NEWLINE_xXTiming of prior therapy:\r\n* Prior hormonal therapy is allowed; hormonal therapy must be discontinued at least 7 days before initiation of protocol therapy\r\n* Ovarian suppression which has been used for > 6 months, during which time there has been disease progression, is allowed concurrently with protocol-based therapy; other hormonal agents (e.g. tamoxifen, aromatase inhibitors, fulvestrant) should be discontinued prior to study entry\r\n* If received, chemotherapy treatment must be discontinued for at least 2 weeks prior to study entry\r\n* Patients must have completed radiation therapy at least 7 days prior to beginning protocol treatment\r\n* Patients must have sufficiently recovered from all reversible toxicities related to prior therapy before beginning protocol treatment, with the exception of alopeciaXx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, radiotherapy or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation)Xx_NEWLINE_xXAny prior treatment for the current breast cancer, including chemotherapy, hormonal therapy, radiation or experimental therapyXx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy\n             that is considered to be investigational (i.e., used for non-approved indications(s)\n             and in the context of a research investigation). Use of low dose corticosteroid\n             therapy (e.g., for nausea prophylaxis) is acceptable; however, concomitant tamoxifen\n             therapy is not. Supportive care measures are allowed.Xx_NEWLINE_xXHas received previous high dose (>= 600,000 IU/kg) IL-2 therapy; other prior therapy (in the adjuvant or the metastatic setting) is allowed, including immunotherapy, targeted therapy, chemotherapy, or experimental therapyXx_NEWLINE_xXAt least 2 weeks have passed since prior chemotherapy, biological therapy, radiation therapy, major surgery, other investigational or anti-cancer therapy that is considered disease-directedXx_NEWLINE_xXPatients must have recovered to at least a grade =< 1 toxicity eligibility levels due to adverse events (AEs) and/or toxicity of prior chemotherapy or biologic therapy; they must not have had chemotherapy or biologic therapy within 4 weeks (6 weeks for nitrosoureas and mitomycin C, or 2 months for UCN-01), or therapy with tyrosine kinase inhibitors within 5 times the half-life of the inhibitors prior to entering the study; patients must be >= 2 weeks since any prior administration of study drug in an exploratory investigational new drug (IND)/phase 0 study; patients must be >= 1 month since completion of any prior radiation (>= 2 weeks for palliative radiation therapy); however, patients receiving bisphosphonates for any cancer or undergoing androgen deprivation therapy for prostate cancer are eligible for this therapy\r\n* Prior therapy with topoisomerase I inhibitors is allowedXx_NEWLINE_xXPrior therapy:\r\n* Patients with recurrent, metastatic triple negative breast cancer must have had at least 1 chemotherapy regimen for metastatic breast cancer or have developed metastatic breast cancer within 1 year of completion of adjuvant chemotherapy\r\n* Prior therapy for high grade serous platinum-sensitive ovarian cancer patients must have included 2 prior platinum-based chemotherapy regimens\r\n* Participants must be at least 4 weeks since prior radiation therapy, 3 weeks since prior chemotherapy, and 6 weeks if the last regimen included carmustine (BCNU) or mitomycin C\r\n* No small-molecular kinase inhibitors or any other type of investigational agent within 4 weeks before the first dose of study treatment or 5 half-lives of the compound or active metabolite, whichever is shorter\r\n* For any hormonal therapy, participants must have stopped them at least 1 week prior to initiating therapy\r\n* Amount of prior radiotherapy: participants may not have had > 25% of their bone marrow radiatedXx_NEWLINE_xXPatients must not be planning to receive any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment; concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptableXx_NEWLINE_xXOther concurrent chemotherapy or any ancillary therapy considered investigational\r\n* NOTE: Bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatmentXx_NEWLINE_xXReceiving other concurrent anticancer therapy (including chemotherapy, radiation, hormonal treatment, or immunotherapy, but excluding corticosteroids) within 7 days prior to the ASCT or planning to receive any of these treatments prior to the last study visit on day +100Xx_NEWLINE_xXConcurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than study treatment regorafenib; however, the palliative radiation therapy (XRT) to non-targeted lesions is allowedXx_NEWLINE_xXPatients must not be planning to receive any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment; concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptableXx_NEWLINE_xXPatients must not be planning to receive any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment; concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptableXx_NEWLINE_xXPrevious anti-cancer chemotherapy, immunotherapy or investigational agents < 4 weeks prior to the first day of study defined treatmentXx_NEWLINE_xXOther ongoing systemic therapy for cancer, including any other experimental treatment; these include concomitant therapy with any of the following: interleukin (IL)-2, interferon, ipilimumab or other immunotherapy; cytotoxic chemotherapy; and targeted therapiesXx_NEWLINE_xXPrior therapy:\r\n* The patient’s malignancy must have relapsed after or failed to respond to frontline curative therapy and/or there must not be any curative treatment options available at the time of study entry\r\n* There is no limit to the number of prior treatment regimens; however, patients must have fully recovered from the acute toxic effects of prior chemotherapy, immunotherapy, or radiotherapy prior to study enrollment; any grade 3 or 4 non-hematologic toxicity of any previous therapy must have resolved to grade 2 or less\r\n* Myelosuppressive chemotherapy: patients must not have received myelosuppressive chemotherapy within 3 weeks of enrollment (6 weeks if prior nitrosourea)\r\n* Hematopoietic growth factors: at least 7 days must have elapsed since the completion of therapy with a growth factor; at least 14 days must have elapsed after receiving pegfilgrastim\r\n* At least 7 days must have elapsed since the completion of therapy with a biologic agent, targeted agent, tyrosine kinase inhibitor or a metronomic non-myelosuppressive regimen\r\n* Monoclonal antibodies: at least 4 weeks must have elapsed since prior therapy that included a monoclonal antibody\r\n* Radiotherapy: 3 weeks must have elapsed since external beam radiation therapy (XRT)Xx_NEWLINE_xXTreatment including radiation therapy (RT), chemotherapy, targeted therapy, or endocrine therapy for the currently diagnosed breast cancer prior to randomizationXx_NEWLINE_xXAny major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 28 days prior to randomization and/or daily or weekly chemotherapy or other approved anti-myeloma therapy without the potential for delayed toxicity within 14 days prior to registrationXx_NEWLINE_xXPrior systemic anti-cancer therapy (chemotherapy with delayed toxicity, extensive radiation therapy, immunotherapy, biologic therapy, or vaccine therapy) within the last 3 weeks; chemotherapy regimens without delayed toxicity within the last 2 weeks preceding the first dose of study treatmentXx_NEWLINE_xXPrior systemic anti-cancer therapy (chemotherapy with delayed toxicity, extensive radiation therapy, immunotherapy, biologic therapy, or vaccine therapy) within the last 3 weeks; chemotherapy regimens without delayed toxicity within the last 2 weeks preceding the first dose of study treatmentXx_NEWLINE_xXConcurrent chemotherapy or biologic therapyXx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation); Note: concomitant use of zoledronic acid, pamidronate or denosumab is allowed (and can be initiated while patients are on study therapy at investigator discretion)Xx_NEWLINE_xXPatients are receiving concurrent anti-cancer therapy (chemotherapy, immunotherapy, biological therapy and hormonal therapy) while taking study medicationXx_NEWLINE_xXPrior anti-cancer therapy (e.g., biologic or other targeted therapy, chemotherapy, hormonal therapy) within 2 weeks prior to day 1 if the patient has recovered from all adverse events (AEs) to grade 1 except for alopeciaXx_NEWLINE_xXPatient must have no plans to receive concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy or any other type of therapy for treatment of cancer while on this protocol treatmentXx_NEWLINE_xXConcurrent treatment with any cytotoxic therapyXx_NEWLINE_xXLast dose of prior chemotherapy, radiation therapy, or investigational agents occurred at least 4 weeks before the start of therapy;Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, abiraterone treatment, enzalutamide treatment, or radiation therapy within 2 weeks prior to first dose of study therapy or who has not recovered (ie, Grade ?1 or at baseline) from AEs due to a previously administered agentXx_NEWLINE_xXConcurrent anti-cancer therapy (chemotherapy, hormonal therapy, radiation therapy, surgery, immunotherapy, tumor embolization, or biologic therapy including pertuzumab, but except IV trastuzumab or hormonal therapy, if patient is already being treated with either of the two agents)Xx_NEWLINE_xXAny concurrent chemotherapy, immune-mediated therapy or biologic or hormonal therapy for cancer treatmentXx_NEWLINE_xXdiscontinued all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, and endocrine therapy), except trastuzumab, for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug, and recovered from the acute effects of therapyXx_NEWLINE_xXChemotherapy, targeted small molecule therapy, or radiation therapy within at least 2 weeksXx_NEWLINE_xXPatients must not be planning to receive concomitant other biologic therapy, radiation therapy, hormonal therapy, other chemotherapy, surgery or other therapy after step 2 registrationXx_NEWLINE_xXThere is no upper limit on prior chemotherapy, targeted therapy, or endocrine therapyXx_NEWLINE_xXPRIOR/CONCURRENT THERAPY CRITERIA: Patients must have documented progressive cancer following at least one but no more than two prior regimens of systemic therapy for lung cancer, one of which must have been platinum based combination chemotherapy; treatment with an immune therapy or targeted therapy for advanced disease will be considered a separate regimen and will count toward the prior regimens; maintenance therapy will not be counted as a separate regimen; adjuvant chemotherapy or chemotherapy administered as part of concurrent chemotherapy and radiation therapy for the treatment of lung cancer will not count as a prior regimen of systemic therapy as long as recurrence of patient’s lung cancer occurred more than 12 months after the last day of chemotherapyXx_NEWLINE_xXAny anti-cancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment (hormonal therapy with gonadotropin-releasing hormone agonists or antagonists for prostate cancer and palliative radiotherapy greater than (>) 2 weeks prior to Cycle 1, Day 1 are allowed)Xx_NEWLINE_xXCurrently receiving chemotherapy, radiation therapy, immunotherapy, or biotherapy for breast cancerXx_NEWLINE_xXMajor surgery within <30 days of starting treatment or received chemotherapy, investigational agents, or other cancer therapy, except hormonal therapy (eg, tamoxifen, aromatase inhibitors), <14 days prior to the initiation of investigational productsXx_NEWLINE_xXAny concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatmentXx_NEWLINE_xXAny prior treatment for the current breast cancer, including chemotherapy, hormonal therapy, radiation or experimental therapyXx_NEWLINE_xXPrior systemic biologic therapy, including immunotherapy, for prostate cancer;Xx_NEWLINE_xXIs taking concurrent (or within 4 week prior to registration) chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy that is considered to be investigational (i.e., used for non-approved indications(s) and in the context of a research investigation). Supportive care measures are allowedXx_NEWLINE_xXTreatment with radiation therapy, surgery, chemotherapy, or investigational therapy within 28 days prior to study entry.Xx_NEWLINE_xXPrior therapy\r\n* Patients must have recurred or progressed following at least one platinum-based chemotherapy regimen\r\n* Patients may have received an unlimited number of prior therapy regimens\r\n* Patients may not have received all of the five choices in the “standard therapy” arm\r\n* Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration\r\n* Any other prior therapy directed at the malignant tumor, including chemotherapy and radiation therapy, must be discontinued at least 4 weeks prior to registration; any investigational agent must be discontinued at least 28 days prior to registrationXx_NEWLINE_xXPatients may have received prior hormonal therapy for treatment of endometrial carcinoma; all hormonal therapy must be discontinued at least one week prior to the first date of study therapyXx_NEWLINE_xXPatients must not have received any prior systemic therapy (chemotherapy or other biologic therapy) for lung cancerXx_NEWLINE_xXPatients must not have received any prior anti-cancer therapy (except for radical or partial nephrectomy noted above) for renal cell carcinoma, including systemic therapy in the adjuvant or neoadjuvant setting, immunotherapy, investigational therapy, surgical metastasectomy, or radiation therapyXx_NEWLINE_xXPatients must not be planning to receive any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment; concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptableXx_NEWLINE_xXAny concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment.Xx_NEWLINE_xXPatients must not have received prior surgery, radiation therapy, chemotherapy, targeted therapy, or any investigational therapy for pancreatic cancerXx_NEWLINE_xXAny anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatmentXx_NEWLINE_xXCompletion of all therapy (including surgery, radiotherapy, chemotherapy, immunotherapy, or investigational therapy) for the treatment of cancer ? 4 weeks before the start of study therapy.Xx_NEWLINE_xXAny concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatmentXx_NEWLINE_xXChemotherapy, immunotherapy, biologic therapy, or any other anticancer therapy within 2 weeks (or five elimination half lives for noncytotoxics, whichever is shorter) of Day 1 of trial drug treatment (6 weeks for nitrosureas or mitomycin). Subjects on therapy with trastuzumab (trastuzumab cohort) may continue with trastuzumab during the screening phase of the study. Subjects on endocrine therapy may continue with antihormonal therapy until Day 1 of the study.Xx_NEWLINE_xXAny anticancer therapy, including: small molecules, immunotherapy, chemotherapy, monoclonal antibody therapy, radiotherapy or any other agents to treat cancer (anti-hormonal therapy given as adjuvant therapy for early-stage estrogen receptor (ER) positive breast cancer is not considered cancer therapy for the purpose of this protocol)Xx_NEWLINE_xXWould receive study treatment within 3 weeks from radiation therapy, experimental therapy, hormonal therapy, prior chemotherapy, or biological therapy; use an invasive investigational device; or is currently enrolled in an investigational studyXx_NEWLINE_xXPrior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to Study Day 1Xx_NEWLINE_xXAnti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, or investigational agent) within 28 days prior to study day 1Xx_NEWLINE_xXConcurrent investigational therapy or investigational therapy within 4 weeks of start of afatinib therapyXx_NEWLINE_xXUse of hormonal therapy or biologic therapy for prostate cancer (other than approved bone targeting agents and GnRH agonist/antagonist therapy) or use of an investigational agent within 4 weeks of randomization;Xx_NEWLINE_xXAnti-tumor therapy within 28 days of study drug dosing; concurrent use of hormone therapy for breast or prostate cancer is permittedXx_NEWLINE_xXTreatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational anti-cancer agent within 2 weeks prior study startXx_NEWLINE_xXAt least 2 weeks since prior chemotherapy, biological therapy, radiation therapy, major surgery, other investigational, or anti-cancer therapy that is considered disease-directed and recovered from prior toxicities to grade 0-1 at least 2 weeks prior to investigational therapyXx_NEWLINE_xXNo anti-cancer treatment including surgery, radiotherapy, chemotherapy, other immunotherapy, or investigational therapy within 14 days before treatment startXx_NEWLINE_xXAny other prior therapy directed at the malignant tumor, including chemotherapy, bevacizumab or other biologic or targeted agents and immunologic agents, must be discontinued at least 21 days (three weeks) prior to registration.Xx_NEWLINE_xXAny systemic anti-cancer therapy (e.g. chemotherapy, immunotherapy or biological therapy [including monoclonal antibodies]) within 28 days prior to beginning study therapy.Xx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, radiotherapy, or investigational therapy.Xx_NEWLINE_xXAny systemic anti-cancer therapy (e.g., chemotherapy, immunotherapy or biological therapy (including monoclonal antibodies), or experimental anti-cancer therapy) within 28 days prior to beginning study therapy. Note: Ongoing castrating therapy with a GnRH agonist or antagonist is mandatory to assure a castrate level of serum testosterone <50 ng/dL, except in patients who have undergone an orchiectomy. Bisphosphonates or denosumab continuation is permissible (i.e., no change for 30 days prior to Cycle 1 Day 1). Patients who receive a dose of EC1169 under another Endocyte protocol do not need a washout period for EC1169Xx_NEWLINE_xXThe subject has received chemotherapy, immunotherapy, or any other systemic anticancer therapy, with the exception of anti-HER2 therapy (e.g., trastuzumab), within 14 days prior to the Day 1 visit.Xx_NEWLINE_xXPrevious anti-cancer treatment (cytotoxic chemotherapy, immunotherapy, biologic therapy radiotherapy or investigational agents) with therapeutic intent for current breast cancer.Xx_NEWLINE_xXSubject has received anticancer therapy including chemotherapy, radiation therapy, immunotherapy, biologic, or any investigational therapy within a period of 21 days or anti-cancer herbal therapy within 7 days prior to Cycle 1 Day 1 of ABT-165.Xx_NEWLINE_xXCurrent concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocolXx_NEWLINE_xXPrior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to first dose of study drugXx_NEWLINE_xXAny approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3 weeks prior to initiation of study treatment, with the following exceptions: hormone-replacement therapy or oral contraceptives; tyrosine kinase inhibitors (TKIs) that have been discontinued > 7 days prior to cycle 1, day 1; screening scans must be obtained after discontinuation of prior TKIsXx_NEWLINE_xXHas had prior anti-cancer monoclonal antibody (mAb), chemotherapy, targeted small molecule therapy, or radiation therapy within 4 weeks prior to the planned first dose of the studyXx_NEWLINE_xXReceipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) 21 days prior to the first dose of study drugXx_NEWLINE_xXPatients receiving concurrent anti-cancer therapy (chemotherapy, immunotherapy, radiation therapy, hormonal therapy, and biological therapy) while taking study medication or have previously received talimogene laherparepvec or any other oncolytic virusXx_NEWLINE_xXPatients with metastatic sites that requires chemotherapy and/or non-hormonal targeted therapyXx_NEWLINE_xXDisease not amenable to standard treatment (nonresectable or disease present after one or more surgeries and/or sandostatin treatment) or subject has failed existing first line chemotherapy, biologic therapy, targeted agent therapy or radiation therapyXx_NEWLINE_xXChemotherapy, biologic therapy (antibodies and biologically targeted small molecules)Xx_NEWLINE_xXConcurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than study treatment (regorafenib, other agents being investigated in combination with regorafenib).Xx_NEWLINE_xXNo more than sixty days from final surgery to simulation if no systemic therapy (includes chemotherapy and hormonal therapy) is givenXx_NEWLINE_xXUp to 4 prior lines of systemic therapy (biologic or chemotherapy) are allowed; maintenance therapy after 4-6 cycles of front-line chemotherapy is still considered 1 line of therapy and is not considered 2 separate therapiesXx_NEWLINE_xXNo treatment for current primary invasive adenocarcinoma of the breast such as irradiation, chemotherapy, immunotherapy, investigational therapy or surgery; previous treatment for breast and/or ovarian cancer with chemotherapy, endocrine therapy, surgery and radiation are allowed if >= 3 years prior to current diagnosis and there is no clinical evidence of metastatic diseaseXx_NEWLINE_xXProgression on at least one prior systemic chemotherapy for advanced, unresectable or metastatic disease; prior adjuvant or neoadjuvant therapy is not included as prior systemic chemotherapy unless treatment occurred within the 6 months prior to study enrollment\r\n* There is no limit to the number of prior lines of treatment a patient has received\r\n* No treatment with biologic therapy, immunotherapy, chemotherapy, investigational agent for malignancy, or radiation =< 28 days before study registration; no treatment with nitrosourea or mitomycin =< 42 days before study registration\r\n* Patients should have resolution of any toxic effects of prior therapy (except alopecia) to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, grade 1 or lessXx_NEWLINE_xXHave discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, and investigational therapy) for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug, and recovered from the acute effects of therapy (treatment related toxicity resolved to baseline) except for residual alopecia.Xx_NEWLINE_xXPrior non-hormonal therapy for the present breast cancer, including radiation therapy or chemotherapyXx_NEWLINE_xXConcurrent chemotherapy, hormonal therapy, immunotherapy regimens, or radiation therapy, standard or investigationalXx_NEWLINE_xXTreatment including chemotherapy, chemo-immunotherapy, monoclonal antibody therapy, radiotherapy, high-dose corticosteroid therapy (more than 60 mg prednisone daily or equivalent), or immunotherapy within 21 days prior to enrollment or concurrent with this trialXx_NEWLINE_xXUse of chemotherapy, immunomodulating therapy, biologic therapy, radiation therapy, or investigational therapy within 4 weeks of the first dose of study drugXx_NEWLINE_xXPrior chemotherapy, immunotherapy, or targeted therapy is allowed as long as it did not include dasatinibXx_NEWLINE_xXReceiving concurrent chemotherapy, biologic therapy, radiotherapy, or other investigational therapyXx_NEWLINE_xXPatients may not receive any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement) while on this study other than hydroxyurea for control of countsXx_NEWLINE_xXReceived any anti-cancer therapy including chemotherapy or radiotherapy, steroid therapy for anti-neoplastic intent, and investigational therapy, including targeted small molecule agents within 28 days prior to the first dose of study drug or has not recovered to less than Grade 2 clinically significant adverse effect(s)/toxicity(s) of the previous therapyXx_NEWLINE_xXHistory of any systemic or local therapy (e.g., chemotherapy, biologic or targeted therapy, hormonal therapy, or photodynamic therapy) for the treatment or prevention of melanoma, including interferon alpha-2b and pegylated interferon alpha-2bXx_NEWLINE_xXA concurrent active cancer that requires non-surgical therapy (e.g. chemotherapy, radiation, adjuvant therapy)Xx_NEWLINE_xXPrior use of anti-HER2 therapy for any reason or other prior biologic or immunotherapy for cancerXx_NEWLINE_xXConcomitant use of any anti-cancer therapy or radiation therapy, or any other investigational agentXx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation)Xx_NEWLINE_xXRadiation therapy, hormonal therapy, biologic therapy, experimental therapy, or chemotherapy for cancer =< 21 days prior to registrationXx_NEWLINE_xXPrior chemotherapy, biological therapy, radiation therapy, hormonal therapy for anti-cancer purposes, targeted therapy, or other investigational anticancer therapy (not including palliative radiotherapy at focal sites) within 21 days prior to the first dose of trial treatment;Xx_NEWLINE_xXChemotherapy, Tyrosine Kinase Inhibitor therapy, radiation therapy or hormonal therapy within 2 weeksXx_NEWLINE_xXImmunotherapy or biological therapy, or investigational agent within 3 weeks (Note: Some cohort exceptions allow anti-PD-1 therapy)Xx_NEWLINE_xXTreatment for this cancer including surgery, radiation therapy, chemotherapy, biotherapy, hormonal therapy or investigational agent prior to study entryXx_NEWLINE_xXConcurrent usage of other investigational agents, chemotherapy, or hormone therapy; prior chemotherapy, hormonal therapy, targeted therapy, and investigational agents are allowed but all toxicities grade >= 2 must have resolved by the time of study commencement (except alopecia)Xx_NEWLINE_xXHas had prior radiation, chemotherapy, targeted therapy, or investigational therapy for cervical cancer\r\n* Note: if subject received major surgery for reason other than cervical cancer, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting treatmentXx_NEWLINE_xXParticipants cannot have received any anti-neoplastic therapy (including radiotherapy, chemotherapy or immunotherapy) after ASCTXx_NEWLINE_xXAny prior chemotherapy, targeted/biologic therapy, or radiation for treatment of the participant’s gastric or GE junction cancerXx_NEWLINE_xXReceiving concomitant chemotherapy, radiation therapy, or immunotherapy during the duration of treatment on protocol, or within 21 days prior to enrollmentXx_NEWLINE_xXPrior chemotherapy, targeted therapy, immunotherapy, or any clinical trials or radiotherapy for pancreatic cancerXx_NEWLINE_xXPrior chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, other anticancer agents within 21 days of starting study treatment (not including palliative radiotherapy at focal sites); prior use of an investigational monoclonal antibody therapy within 3 months, or prior use of nitrosoureas or mitomycin C within 6 weeks; patients must have recovered from acute toxicity due to radiotherapyXx_NEWLINE_xXAre receiving concurrent treatment with other anticancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, chemoembolization, or targeted therapy or radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 4 weeks prior to enrollment.Xx_NEWLINE_xXParticipants who require active chemotherapy for another cancer; those requiring hormonal therapy or radiation therapy may be considered for enrollment on a case by case basisXx_NEWLINE_xXConcurrent anti-cancer therapy (chemotherapy, definitive radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than study treatment; concurrent therapy with bisphosphonates or denosumab for bone metastases is allowed; palliative radiation to non-target lesions is also allowedXx_NEWLINE_xXReceipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) < 21 days prior to the first dose of study drugXx_NEWLINE_xXPatients may not have received prior cytotoxic chemotherapy; however, nonplatinum/non-taxane chemotherapy used for radiation sensitization is allowed; patients may have received prior radiation therapy (including whole pelvic or vaginal brachytherapy), hormonal therapy, or therapy with biologic agents, but such therapy must be discontinued at least 2 weeks prior to entry on this studyXx_NEWLINE_xXAny major surgery, radiotherapy, chemotherapy, biologic therapy, immunotherapy, experimental therapy within 2 weeks prior to the first dose of the study drugsXx_NEWLINE_xXPrior therapy such as chemotherapy or radiation therapy or anti-tumor experimental therapy for pancreatic cancerXx_NEWLINE_xXAny concurrent chemotherapy, investigational product , biologic, or hormonal therapy for cancer treatment.Xx_NEWLINE_xXPrior anti-cancer mAb, chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to first dose of study medication or not recovered from adverse events due to a previously administered agentXx_NEWLINE_xXCompletion of all therapy for the treatment of cancer 2 weeks before the start of study therapy and recovered.Xx_NEWLINE_xXCurrently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy) or investigational anti-cancer drugXx_NEWLINE_xXPatient is expected to require any other form of antineoplastic therapy while on study; including systemic chemotherapy, biological therapy, immunotherapy not specified in this protocolXx_NEWLINE_xXChemotherapy, immunotherapy (including interferon), or biological therapy, radiation therapy and/or surgery within 4 weeks prior to first dose of study drug.Xx_NEWLINE_xXConcurrent treatment with commercial agents or other agents with the intent to treat the participant’s malignancy, including endocrine therapy, chemotherapy, and/or targeted therapy, with the exception of bisphosphonates and GnRH agonistsXx_NEWLINE_xXConcurrent anti-platelet therapyXx_NEWLINE_xX> 4 weeks of tamoxifen therapy, or other hormonal therapy, for adjuvant therapy for this malignancy\r\n* NOTE: if the patient has received < 4 weeks of such therapy but is still receiving it at the time of entry into the study, patient must temporarily stop the therapy; the therapy can re-start only after 12 weeks of T-DM1 has been administeredXx_NEWLINE_xXTreatment with hormonal therapy (eg, androgen receptor inhibitors, 5-alpha reductase inhibitors) or biologic therapy for prostate cancer (other than LHRH analogue therapy) within 4 weeks before enrollment;Xx_NEWLINE_xXPrior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or not recovered from adverse events due to a previously administered agent or surgeryXx_NEWLINE_xXConcurrent anti-cancer therapy =< 4 weeks from registration (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization)Xx_NEWLINE_xXNo limit in number of prior hormonal agents in metastatic breast cancer; only one prior chemotherapy is allowed in metastatic setting; anti-HER2 targeting therapy, CDK4/6 inhibitor, other targeted therapy (e.g., mTOR or PI3K inhibitor) in combination with hormonal treatment will be counted as one hormonal agent; any anti-HER2 targeting therapy in combination with chemotherapy will not be counted as one additional treatmentXx_NEWLINE_xXExcluded therapies and medications, previous and concomitant:\r\n* Concurrent anti-cancer therapy (chemotherapy, surgery, immunotherapy, biologic therapy, anti-HER2 targeting therapies, or tumor embolization) other than Ra 223 dichloride; concurrent external beam radiation therapy is permitted\r\n* Prior use of Ra-223 dichloride\r\n* Concurrent use of another investigational drug or device therapy (i.e., outside of study treatment) during, or within 4 weeks of trial entry (signing of the informed consent form)Xx_NEWLINE_xXSubjects who have plans to receive other concomitant or post treatment adjuvant antineoplastic therapy while on this protocol including surgery, cryotherapy, conventionally fractionated radiotherapy, hormonal therapy, or chemotherapy given as part of the treatment of prostate cancerXx_NEWLINE_xXPatient must not have received any cancer-directed therapy (e.g., surgery, chemotherapy, radiation therapy, biologic therapy) for the index diagnosisXx_NEWLINE_xXPrior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or not recovered from AEs due to a previously administered agentXx_NEWLINE_xXAny concurrent chemotherapy, Investigational Product, biologic, or hormonal therapy for cancer treatment;Xx_NEWLINE_xXReceipt of last dose of an approved (marketed) anticancer therapy (chemotherapy, targeted therapy, biologic therapy, mAbs, etc) within 21 days prior to the first dose of study treatment;Xx_NEWLINE_xXAny treatment, including radiotherapy, chemotherapy, and/or targeted therapy, administered for the currently diagnosed breast cancer prior to study entry.Xx_NEWLINE_xXConcurrent anti-cancer therapy, including chemotherapy agents, targeted agents, or biological agents not otherwise specified in this protocolXx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational; prior therapy with bisphosphonate is allowed; prior radiation therapy to a solitary plasmacytoma is allowed; prior clinical trials or therapy for smoldering MM or monoclonal gammopathy of undetermined significance (MGUS) are allowed but should be discussed with the principal investigatorXx_NEWLINE_xXAny other prior therapy directed at the malignant tumor, including chemotherapy, biologic/targeted therapy and immunologic therapy, must be discontinued at least 3 weeks prior to study treatment initiationXx_NEWLINE_xXPatients receiving cancer therapy (i.e., chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization) within 3 weeks of cycle 1/day 1 with the following exceptions:\r\n* Limited palliative radiation is allowed if completed >= 2 weeks of cycle 1 day 1 (C1D1)\r\n* Corticosteroid therapy (prednisone or equivalent =< 20 mg daily) is allowed as clinically warranted as long as the dose is stabilized at least for 7 days prior to initial dosing; topical or inhaled corticosteroids are permitted\r\n* Patients currently taking ibrutinib do not need to undergo a washout periodXx_NEWLINE_xXPrior chemotherapy, radiation therapy, or immunotherapy for prostate cancerXx_NEWLINE_xXPrior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks of study Day 1 or not recovered from adverse events due to a previously administered agentXx_NEWLINE_xXPrior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1Xx_NEWLINE_xXPatient who has had chemotherapy, radiation, or biological cancer therapy within 14 days prior to the first dose of study drugXx_NEWLINE_xXAny concurrent chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer treatment.Xx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation)Xx_NEWLINE_xXDiscontinuation of all prior chemotherapy, immunotherapy, or biological therapy at least 3 weeks prior to the first dose of investigational product is required.Xx_NEWLINE_xXPatients who have had prior chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, other anticancer agents, and any investigational agents within 28 days of starting study treatment (not including palliative radiotherapy at focal sites), or corticosteroids that are prohibited per protocol within 14 days of starting study treatmentXx_NEWLINE_xXAny concurrent chemotherapy, Investigational Product, biologic, or hormonal therapy for cancer treatmentXx_NEWLINE_xXReceipt of last dose of an approved (marketed) anticancer therapy (chemotherapy, targeted therapy, biologic therapy, mAbs, etc) within 21 days prior to the first dose of study treatmentXx_NEWLINE_xXConcurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than the protocol based treatment; LHRH agonist or antagonist therapy and bisphosphonates or denosumab are allowedXx_NEWLINE_xXSmall molecule therapy, radiotherapy, immunotherapy, monoclonal antibodies, or chemotherapy within 2 weeks before first dose of study drugXx_NEWLINE_xXAny previous systemic therapy (including chemotherapy, immunotherapy, HER2 targeted agents, and antitumor vaccines) for cancer, or radiation therapy for cancerXx_NEWLINE_xXMost recent chemotherapy, immunotherapy, chemo-immunotherapy, or investigational agents <21 days of the first dose of study treatment. Most recent targeted therapy <14 days of the first dose of study treatment.Xx_NEWLINE_xXRadiation, chemotherapy, immunotherapy or any other systemic anticancer therapy =< 3 weeks prior to initiation of therapyXx_NEWLINE_xXConcurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than study treatmentXx_NEWLINE_xXTreatment with chemotherapy, radiation therapy, or other immunotherapy =< 4 weeks prior to registrationXx_NEWLINE_xXConcurrent anti-cancer therapy (chemotherapy, definitive radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than study treatment; concurrent therapy with bisphosphonates or denosumab for bone metastases is allowed; palliative radiation to non-target lesions is also allowedXx_NEWLINE_xXAny concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment.Xx_NEWLINE_xXTreatment with systemic biologic therapy for prostate cancer (other than approved bone targeted agents and GnRH-analogue therapy) or other agents with anti-tumor activity within 4 weeks of enrollment (day 1 visit)Xx_NEWLINE_xXPatients who have received prior anti-cancer therapy (e.g., biologic or other targeted therapy, chemotherapy, hormonal therapy) within 2 weeks prior to registration are not eligible for participationXx_NEWLINE_xXAny approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment; the following exception are allowed: Hormone-replacement therapy or oral contraceptives tyrosine-kinase inhibitors (TKIs) approved for treatment of NSCLC discontinued >7 days prior to Cycle 1, Day 1Xx_NEWLINE_xXAnti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents within 7 days of the first dose of BBI608.Xx_NEWLINE_xXAny approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatmentXx_NEWLINE_xXFor the currently diagnosed breast cancer, any previous systemic anti-cancer treatment (for example, neoadjuvant or adjuvant), including but not limited to, chemotherapy, anti-HER2 therapy (for example, trastuzumab, trastuzumab emtansine, pertuzumab, lapatinib, neratinib, or other tyrosine kinase inhibitors), hormonal therapy, OR anti-cancer radiation therapy (RT) (intra-operative radiotherapy as a boost at the time of primary surgery is acceptable)Xx_NEWLINE_xXPatient who received any prior systemic anti-cancer therapy (including hormonal therapy and chemotherapy) for advanced breast cancer Note:Xx_NEWLINE_xXTreatment with any of the following anti-cancer therapies:\r\n* Radiation therapy, surgery or tumor embolization within 14 days prior to the first dose of study treatmentXx_NEWLINE_xXPrior treatment with: BRAF and/or MEK inhibitor(s); anti-cancer therapy (e.g., chemotherapy with delayed toxicity, immunotherapy, biologic therapy or chemoradiation) within 21 days or prior nitrosourea or mitomycin C containing therapy within 42 days prior to enrollment and/or prior daily or weekly chemotherapy or biologic therapy without the potential for delayed toxicity within 14 days prior to enrolment or prior nvestigational drug(s) within 30 days or 5 half-lives, whichever is longer, prior to enrollmentXx_NEWLINE_xXAny major surgery =< 28 days prior to the initiation of investigational products, or received anti-cancer therapy (including chemotherapy, biological therapy, hormonal therapy, investigational agents, or other anti-cancer therapy) administered =< 14 days prior to the initiation of investigational productsXx_NEWLINE_xXParticipants who have received anti-cancer therapy (including chemotherapy, biological therapy, investigational agents, hormonal therapy, or other anti-cancer therapy) or radiotherapy within =< 14 days prior to the planned initiation of investigational products, or those who have not recovered to grade =< 1 from adverse events due to their most recent therapy (excepting alopecia)Xx_NEWLINE_xXPatients receiving concurrent anti-cancer therapy (chemotherapy, immunotherapy, radiation therapy and biological therapy) while taking study medication; however, patients receiving CDK4/6 inhibitor ormTOR inhibitor as a standard of care while on study is permittedXx_NEWLINE_xXPrior chemotherapy or biologic therapy for the same HNSCC; prior chemotherapy or biologic therapy for a different previous HNSCC is allowedXx_NEWLINE_xXReceiving concomitant chemotherapy, radiation therapy, or immunotherapy during the duration of treatment on protocolXx_NEWLINE_xXParticipants receiving any other cancer directed concurrent therapy; such as concurrent chemotherapy, radiotherapy, or hormonal therapy; concurrent treatment with bisphosphonates/denosumab is allowed but should be started before starting treatment on studyXx_NEWLINE_xXPatients may have received prior systemic therapy (chemotherapy, immunotherapy, biologic therapy, or combination regimens); all adverse events associated with prior treatment must have resolved to =< grade 1 prior to registrationXx_NEWLINE_xXPatient must not have received chemotherapy, biologic therapy, or any other investigational drug for any reason within 28 days prior to start of therapy, and must have recovered from toxicities of prior therapy to grade 1 or lessXx_NEWLINE_xXPatients must have been diagnosed with the current breast cancer >= 3 and =< 60 months from planned baseline visit date; in addition, participants must have completed local therapy (i.e. surgery and radiation therapy) and any planned preoperative or adjuvant chemotherapy within >= 3 months prior to registration; NOTE: concurrent anti-human epidermal growth factor receptor 2 (HER2) therapy is permitted; concurrent endocrine breast cancer therapy is permitted; patients may enroll >= 3 months after initiation of hormone therapy and if expected to continue the same endocrine/hormone agent for the duration of the study (i.e., care should be taken to ensure a participant enrolling near 5 years since time of hormone treatment initiation will continue the same agent for at least 12 months, switching hormone therapy on study should be avoided); concurrent enrollment in other interventional or drug clinical trials is at the discretion of the protocol chairXx_NEWLINE_xXConcurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than sorafenibXx_NEWLINE_xXPatients who have received chemotherapy or radiotherapy within 4 weeks prior to enrollment are NOT eligible for participation \r\n* The exception to this is patients who are refractory to conventional initial induction chemotherapy (=< 2 courses) or to radiation; patients must have morphologic proof (from bone marrow aspirate, smears, or touch preps of marrow biopsy) of AML with > 10% blasts within 2 weeks prior to initiation of study therapy\r\n* The last dose of cytotoxic therapy (NOT including Hydrea, which is allowed) must have been given >= 14 days prior to initiation of study therapy\r\n* The last dose of biologic therapy must have been given >= 7 days prior to initiation of study therapy\r\n* The last dose of any investigational agent must have been given >= 14 days prior to initiation of study therapyXx_NEWLINE_xXConcurrent chemotherapy, radiotherapy, or any ancillary therapy considered investigational; NOTE: Bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatmentXx_NEWLINE_xXConcomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in this protocolXx_NEWLINE_xXConcurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization)Xx_NEWLINE_xXTreatment with any of the following anti-cancer therapies:\r\n* Radiation therapy, chemotherapy, immunotherapy, biologic therapy, investigational therapy\r\n* Surgery or tumor embolization within 14 days prior to the first dose of pazopanib OR\r\n* Hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanibXx_NEWLINE_xXNo limit on prior lines of endocrine therapy or biologic therapy; endocrine therapy and biologic therapy must be discontinued at least 7 days prior to initiation of protocol therapyXx_NEWLINE_xXAny prior chemotherapy, radiation therapy, or biologic therapy (“targeted therapy”) for treatment of the patient’s pancreatic tumorXx_NEWLINE_xXPatients who have received systemic anti-cancer therapy such as chemotherapy, immunotherapy and/or biologic therapy =< 4 weeks prior to study entry; concurrent anti-cancer therapy (chemotherapy, immunotherapy, biologic therapy) other than the ones specified in the protocol is not permitted during study participation; patients must have discontinued the above cancer therapies for 4 weeks prior to the first dose of study medication, as well as recovered from toxicity (to =< than grade 1, except for alopecia) induced by previous treatments; any investigational drugs should be discontinued 4 weeks prior to the first dose of study medicationXx_NEWLINE_xXPatients who have received prior hormonal therapy are excluded from the trial, except for: patients who have received up to 6 months of hormonal therapy as neoadjuvant therapy before radical prostatectomy or while on radiation therapy, as long as more than 1 year has elapsed between discontinuation of the neoadjuvant hormonal therapy and initiation of hormonal treatment for relapsing diseaseXx_NEWLINE_xXPatients currently receiving cancer therapy (i.e., chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization)Xx_NEWLINE_xXConcurrent systemic and local anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than sorafenibXx_NEWLINE_xXConcurrent treatment with other anticancer therapy, including other chemotherapy, immunotherapy, hormonal therapy, radiotherapy, chemo-embolization, targeted therapy, or an investigational agentXx_NEWLINE_xXAnti-cancer therapy, such as chemotherapy, immunotherapy, hormonal, targeted therapy, or investigational agents within four weeks or five times of the drug half life, whichever is longer, of the first dose of ARQ 087Xx_NEWLINE_xXPrior cytotoxic chemotherapy or biologic therapy for prostate cancerXx_NEWLINE_xXBreast cancer patients must be at least 3 months post-active treatment (including chemotherapy, radiation therapy, endocrine therapy, and/or maintenance therapy), but not greater than 5 years post-active treatment (exception: aromatase inhibitors (AIs) are required, and monoclonal antibodies are allowed)Xx_NEWLINE_xXPatient must not have had chemotherapy, immunotherapy, biologic therapy, hormonal therapy, or investigational therapy within 14 days or 5 half-lives of the drug prior to the first dose of pazopanib; for patients enrolling in the phase I portion of this study, this requirement does not apply to prior treatment with cetuximabXx_NEWLINE_xXAny concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment.Xx_NEWLINE_xXAny prior or concurrent investigational or standard therapy for treatment of metastatic NSCLC including radiation therapy, chemotherapy, biological therapy (with the exception of tyrosine kinase inhibitor as a single agent, which must be at least 5 half-lives prior to day 1, and/or immunotherapy, such as a programmed cell death 1 [PD-1] or programmed cell death 1 ligand 1 [PD-L1] inhibitor, which the last dose must have been given at least 4 weeks prior to day 1) or hormonal therapy; (palliative-targeted radiotherapy for brain or bone metastases is permitted providing it has been at least 14 days prior to day 1)Xx_NEWLINE_xXAt least two weeks since receipt of any biological therapy, chemotherapy, and/or radiation therapyXx_NEWLINE_xXA history of prior radiotherapy, chemotherapy, including infusion or perfusion therapy for current disease or any immunotherapy including tumor vaccines, interferon-alfa, interleukins, levamisole or other biologic response modifiers within the past 4 weeksXx_NEWLINE_xXTreatment with another chemotherapy or hormonal therapy within the past 2 weeksXx_NEWLINE_xXAny prior chemotherapy, targeted/biologic therapy, or radiation for treatment of the patient's pancreatic tumorXx_NEWLINE_xXConcurrent treatment with commercial agents or other agents with the intent to treat the participant’s malignancy, including endocrine therapy, chemotherapy, and/or targeted therapy, with the exception of bisphosphonates and GnRH agonistsXx_NEWLINE_xXAll previous cancer therapy, including radiation, hormonal therapy and surgery, must have been discontinued at least 4 weeks prior to treatment in this studyXx_NEWLINE_xXConcurrent use of other anti-cancer therapy including chemotherapy agents, targeted agents, or biological agents not otherwise specified in this protocolXx_NEWLINE_xXPrior and concurrent therapy:\r\n* Chemotherapy: At least four weeks since prior cytotoxic chemotherapy or 6 weeks since nitrosoureas or mitomycin\r\n* Molecular targeted agents including monoclonal antibodies and tyrosine kinase inhibitors: At least two weeks since last therapy\r\n* Endocrine therapy: Subject may be remain on luteinizing hormone-releasing hormone (LHRH) antagonist therapy for prostate cancer if tumor progression has been confirmed\r\n* Radiotherapy: At least 3 weeks since most recent radiotherapy\r\n* Palliative radiotherapy to localized painful lesions is acceptable when the subject is on study: At least one week after completion of radiation therapy (RT) and recovery from associated toxicities before restarting ARQ 761; irradiated lesions will not be evaluable for response\r\n* Other investigational therapy: At least four weeks since any other investigational therapy\r\n* Concurrent therapy: No other concurrent anticancer or investigational therapy permitted except as noted aboveXx_NEWLINE_xXPrior therapy:\r\n* Prior trastuzumab is allowed for all cohorts\r\n* Prior capecitabine is NOT allowed for participants enrolled to cohorts 3a/3b\r\n* Prior lapatinib is allowed for cohorts 1, 2, 3b but NOT cohort 3a\r\n* No prior therapy with neratinib is allowed\r\n* There is no limit to the number of previous lines of therapy (including chemotherapy, trastuzumab, and endocrine therapies) at least 2 weeks washout period post chemotherapy, any prior protocol therapy, lapatinib, other targeted or biologic therapy, or radiation therapy is required prior to study entry\r\n* No washout is required for hormonal therapy but concurrent hormonal therapy is not allowed for patients on study; the only exception to this is longstanding ovarian suppression in pre-menopausal patients, if this has been started >= 6 months prior to study enrollment; other hormonal therapies are not allowed while patients are on studyXx_NEWLINE_xXPatients who are receiving any cancer-directed concurrent therapy, such as concurrent chemotherapy, radiotherapy, or hormonal therapy while on study; concurrent treatment with bisphosphonates and denosumab is allowed for bony metastases but should be started before the first dose of neratinibXx_NEWLINE_xXPatients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy or radiotherapy) concurrentlyXx_NEWLINE_xXNo prior systemic therapy for lymphoma including chemotherapy or immunotherapy. Patients may have received involved-field radiation therapy which has been discontinued at least 4 weeks prior to treatment in this study.Xx_NEWLINE_xXConcurrent chemotherapy or biologic therapyXx_NEWLINE_xXCurrent concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol; concomitant use of corticosteroids is permitted as clinically indicatedXx_NEWLINE_xXSubjects who received prior chemotherapy, hormonal therapy, immunotherapy or biologic therapy for advanced or metastatic disease with the following exceptions:Xx_NEWLINE_xXTreatment with any of the following anti-cancer therapies: \r\n* Radiation therapy, surgery or tumor embolization within 14 days prior to the first dose of pazopanib OR \r\n* Chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanibXx_NEWLINE_xXOther concurrent chemotherapy, radiotherapy, or any ancillary therapy considered investigational; NOTE: bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatmentXx_NEWLINE_xXHas had any major surgery within the last 28 days, or cytotoxic chemotherapy, biologic therapy, investigational agents, or radiotherapy within the last 21 days and/or has not recovered from prior therapy; patients who have just completed therapy with mitomycin C or nitrosourea will have to wait 42 days before starting therapyXx_NEWLINE_xXCurrently receiving any chemotherapy, investigational agents or registration on another therapy based trial or received chemotherapy with radiation therapy (e.g., temozolomide)Xx_NEWLINE_xXHave discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, and investigational therapy) with the exception of fulvestrant (for Part G only) for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug, and recovered from the acute effects of therapy (treatment related toxicity resolved to baseline) except for residual alopeciaXx_NEWLINE_xXAny of following for the treatment of cancer within 2 weeks of first study treatment: chemotherapy, immunotherapy, experimental therapy or biological therapyXx_NEWLINE_xXTreatment with chemotherapy, hormonal therapy (except hormone replacement therapy, oral contraceptives, or gonadotropin-releasing hormone (GnRH) agonists or antagonists for prostate cancer), immunotherapy, biologic therapy, radiation therapy (except palliative radiation to bony metastases), or herbal therapy as cancer therapy within 4 weeks prior to initiation of ipatasertib. Exceptions are kinase inhibitors approved by local regulatory authorities, which may be used within 2 weeks prior to initiation of ipatasertib, provided that any clinically-relevant drug-related toxicity has completely resolved and prior approval is obtained from the Medical MonitorXx_NEWLINE_xXPrior treatment with any of the following anti-cancer therapies for treatment of their renal cell carcinoma (RCC):\r\n* Radiation therapy, surgery or tumor embolization\r\n* Chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapyXx_NEWLINE_xXCompleted cancer specific therapy (including surgery, radiotherapy and/or chemotherapy) a minimum of 4 weeks prior to entry; (subjects with hormone receptor positive breast carcinoma maintained on hormonal therapy following chemotherapy and radiation are eligible)Xx_NEWLINE_xXAnti-Cancer therapy including chemotherapy, radiation-therapy, immunotherapy, biologic therapy or major surgery within 14 days prior to start of study treatment (Note: Dabrafenib monotherapy within 14 days prior to starting combination therapy is allowed for crossover subjects in Cohort A);Xx_NEWLINE_xXPrior chemotherapy, radiation therapy, immunotherapy, or biotherapy for current breast cancer.Xx_NEWLINE_xXAny number of prior cancer treatments, including investigational agents, chemotherapy, hormone therapy, or targeted therapy are allowedXx_NEWLINE_xXConcurrent investigational treatment, chemotherapy, or targeted therapy; prior chemotherapy, hormonal therapy, targeted therapy, and investigational agents are allowed but all toxicities grade >= 2 must have resolved by the time of study commencement (except alopecia)Xx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation); patients should have recovered from any immunotherapy, chemotherapy, or radiation therapy related toxicitiesXx_NEWLINE_xXAt least 4 weeks since the last dose of chemotherapy, immunotherapy, surgery, or radiation therapy (exception: patients may have received palliative low dose radiation therapy one week before treatment provided it is not given to the only targeted lesions); at least 6 weeks for therapy which is known to have delayed toxicity (nitrosoureas, mitomycin-C, and liposomal doxorubicin); at least 4 weeks (or 5 half-lives, whichever is shorter) since treatment with biologic/targeted therapies; at least 2 weeks since last hormonal therapyXx_NEWLINE_xXPrior non-hormonal therapy or radiation therapy for the current breast cancer; or hormonal therapy within 28 days prior to study entry; or refusal to discontinue hormonal therapyXx_NEWLINE_xXNon-protocol concurrent hormonal therapy is not allowedXx_NEWLINE_xXSystemic anti-cancer therapy, such as chemotherapy, immunotherapy, hormonal, targeted therapy, or investigational agents within four weeks of the first dose of ARQ 087Xx_NEWLINE_xXReceipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) =< 14 days prior to the first dose of study drugXx_NEWLINE_xXReceipt of the last dose of any line of anti-cancer therapy (chemotherapy, immunotherapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, and other investigational agent) 7 days prior to the first dose of study drug and within 6 weeks for nitrosourea or mitomycin C prior radiation therapy to targets other than the site currently being treated is permittedXx_NEWLINE_xXPrior chemotherapy, targeted small molecule therapy, or radiation therapy for current diagnosis of sarcomaXx_NEWLINE_xXAny systemic anti-cancer therapy (including hormonal therapy), radiation, or experimental agent =< 2 weeks of first dose of study treatmentXx_NEWLINE_xXHas received prior chemotherapy, targeted therapy, and radiation therapy within the past 12 months.Xx_NEWLINE_xXReceived last dose of systemic cytotoxic therapy, radiation therapy or therapy with any investigational product within 28 days of enrollment.Xx_NEWLINE_xXReceipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies) < 21 days prior to the first dose of study drug; receipt of the last dose of hormonal therapy within < 7 days prior to the first dose of study drugXx_NEWLINE_xXHad prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to Study Day 1 or who has not recovered from adverse events due to a previously administered agent or major surgeryXx_NEWLINE_xXAny other prior, concurrent or planned chemotherapy, immunotherapy, radiotherapy, device, or investigational therapy for this cancer other than those specified in this study.Xx_NEWLINE_xXReceipt of the last dose or treatment of anti-cancer therapy for the current cancer (chemotherapy, radiotherapy, surgery, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) =< 4 weeks (6 weeks for nitrosoureas or mitomycin C) or > 6 months prior to first dose of study drugXx_NEWLINE_xXNo prior therapy for the tumor, including extensive surgery, radiation therapy, chemotherapy, immunotherapy, targeted therapy or any other investigational agents; surgical biopsy prior to beginning the study is allowableXx_NEWLINE_xXPrior therapy for breast cancer, including irradiation, chemo-, immuno- and/or hormonal therapyXx_NEWLINE_xXAny concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy for treatment of cancerXx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, radiotherapy, or an ancillary therapy considered investigationalXx_NEWLINE_xXUse of concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocolXx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (used for a non-Food and Drug Administration [FDA] approved indication and in the context of a research investigation)Xx_NEWLINE_xXOngoing radiation therapy, chemotherapy, hormonal therapy directed at the tumor, or immunotherapyXx_NEWLINE_xXMajor surgery, chemotherapy, radiotherapy, investigational agents or other cancer therapy within 1 week of treatment day 1Xx_NEWLINE_xXPatients will be excluded if there is a plan to administer non-protocol chemotherapy, radiation therapy, or immunotherapy during the study periodXx_NEWLINE_xXReceived anti-cancer therapy including chemotherapy, immunotherapy, radiation, biologic, any investigational therapy or herbal therapy within a period of 21 days prior to the first dose of ABBV-838, and have unresolved toxicities ? grade 2Xx_NEWLINE_xXConcurrent anticancer therapy (eg, chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, investigational therapy, or tumor embolization).Xx_NEWLINE_xXPatients will be excluded if there is a plan to administer non-protocol chemotherapy, radiation therapy, or immunotherapy during the study period.Xx_NEWLINE_xXPlan to administer non-protocol chemotherapy, radiation therapy, or immunotherapy during the study period.Xx_NEWLINE_xXPatients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents, radiation or immunotherapy) within 4 weeks of the first dose of the study drugXx_NEWLINE_xXPart B only: Prior therapy (including investigational agents) for pancreatic cancerXx_NEWLINE_xXReceived anti-tumor therapy (chemotherapy, investigational product, radiotherapy, retinoid therapy, or hormonal therapy) within 2 weeks (less than 14 days) prior to C1D1 with no residual toxicity >Grade 1; antibody therapy, molecular targeted therapy within 5 half-lives prior to C1D1Xx_NEWLINE_xXPrior anti-tumor therapy (chemotherapy, radiotherapy, antibody therapy, molecular targeted therapy, retinoid therapy or hormonal therapy) within 4 weeks prior to C1D1.Xx_NEWLINE_xXAnti-tumor therapy (chemotherapy, antibody therapy, molecular targeted therapy, or investigational agent) within 28 daysXx_NEWLINE_xXPatients may not have received any prior chemotherapy, biologic therapy or radiation therapy for management of their disease; chemotherapy or biologic therapy administered for treatment of another primary malignancy are permitted if treatment was greater than 5 years agoXx_NEWLINE_xXPatients who are receiving any chemotherapy, biologic therapy, radiation therapy or any investigational agentXx_NEWLINE_xXChemotherapy, hormonal therapy, radiotherapy (except for brain and extremities) or immunotherapy or therapy with monoclonal antibodies or small tyrosine kinase inhibitors within the past 4 weeks prior to treatment with the trial drugXx_NEWLINE_xXAnti-cancer chemotherapy, experimental cancer therapy including clinical trial, or cancer immunotherapy within 4 weeks prior to the first dose of the investigational drug.Xx_NEWLINE_xXPatients may have had prior chemotherapy or immunotherapy or radiation therapy. Any drug-related adverse events (AEs) identified during prior therapy must have been well-controlled (typically resolution to ? Grade 2), or resolved upon investigator review prior to initiation of the study therapy.Xx_NEWLINE_xXConcurrent ongoing administration of systemic therapy (e.g. chemotherapy), or radiation therapy.Xx_NEWLINE_xXPlanned concurrent anti-cancer therapy (chemotherapy, radiotherapy, immunotherapy, biologic therapy, hormonal therapy) while taking investigational treatmentXx_NEWLINE_xXLess than or equal to 3 weeks since receiving treatment with biologic, small molecule, chemotherapy or other agent for non-small cell lung cancer and 28 days since any prior immunotherapy (such as nivolumab)Xx_NEWLINE_xXConcurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) within 28 days of starting study treatment; palliative radiation is allowedXx_NEWLINE_xXAny major surgery or extensive radiotherapy (except that which is required for definitive treatment of primary uveal melanoma), chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 21 days prior to initiation of study therapyXx_NEWLINE_xXNo prior treatment (irradiation, chemotherapy, hormonal, immunotherapy or investigational, etc.) for breast cancer excluding therapy for ductal carcinoma in situ (DCIS); subjects receiving hormone replacement therapy (HRT) are eligible if this therapy is discontinued at least 2 weeks before starting study therapyXx_NEWLINE_xXOther concurrent anti-tumor, chemotherapy, hormonal therapy, immunotherapy regimens or radiation therapy, standard or investigationalXx_NEWLINE_xXConcomitant chemotherapy, hormonal therapy, immunotherapy, or any other form of cancer treatment.Xx_NEWLINE_xXConcomitant chemotherapy, hormonal therapy, immunotherapy, or any other form of cancer treatment.Xx_NEWLINE_xXConcurrent therapy with any other non-protocol anti-cancer therapyXx_NEWLINE_xXConcurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) within 3 weeks of starting study treatmentXx_NEWLINE_xXChemotherapy and other investigational therapies (targeted or immunotherapy) will require a 3-week washout period before treatment initiationXx_NEWLINE_xXAnti-neoplastic treatment for KS (including chemotherapy, radiation therapy, local therapy including topical fluorouracil [5-FU], biological therapy, or investigational therapy) within four weeks of enrollmentXx_NEWLINE_xXConcurrent anticancer therapy (eg, chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, investigational therapy, or tumor embolization).Xx_NEWLINE_xXChemotherapy or investigational drug therapy for cancer up to 21 days prior to day-1 of study.Xx_NEWLINE_xXare receiving concurrent chemotherapy, radiotherapy, immunotherapy, biological or hormonal treatment for cancer.Xx_NEWLINE_xXPrior anti-cancer treatments are permitted (i.e., chemotherapy, radiotherapy, hormonal, or immunotherapy)Xx_NEWLINE_xXAt least 4 weeks must have elapsed from last dose of prior anti-cancer therapy and the initiation of study therapyXx_NEWLINE_xXHave had systemic anticancer therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy, and/or hormonal therapy within 4 weeks prior to initiation of study treatment.Xx_NEWLINE_xXPrior immunotherapy is allowedXx_NEWLINE_xXInitiation of anti-tumor therapy including chemotherapy or investigational drug treatment within 30 days before beginning studyXx_NEWLINE_xXAt least 2 weeks since the last chemotherapy, radiation therapy, immunotherapy or any investigational productsXx_NEWLINE_xXAny of the following for treatment of this cancer including:\r\n* Surgery\r\n* Radiation therapy\r\n* Chemotherapy\r\n* Biotherapy\r\n* Hormonal therapy\r\n* Investigational agent prior to study entryXx_NEWLINE_xXAt least 2 weeks since the last previous cancer treatment including: chemotherapy, radiation therapy, immunotherapy, surgery, hormonal therapy, or targeted biologics.Xx_NEWLINE_xXRadiation therapy, minor surgery, tumor embolization, chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days prior to the protocol-mandated 4-week drug holiday.Xx_NEWLINE_xXPrior chemotherapy, immunotherapy or radiation for pancreatic cancerXx_NEWLINE_xXIs receiving any other concurrent systemic tumor therapy, including hormonal agents and HER-2 inhibitorsXx_NEWLINE_xXPrior chemotherapy, hormonal therapy, biologic therapy, investigational agent, targeted therapy or radiation therapy for current breast cancer; patients with history of breast cancer greater than 5 years from initial diagnosis are eligible for the study; patients may not have received anthracycline-based chemotherapy in the past; patients with history of ductal carcinoma in situ (DCIS) are eligible if there were treated with surgery aloneXx_NEWLINE_xXPatients must not have had major surgery, radiation therapy, chemotherapy, biologic therapy (including any investigational agents), or hormonal therapy (other than replacement), within 4 weeks prior to entering the study and must have evidence of stable or progressive disease to be eligibleXx_NEWLINE_xXConcurrent therapy for cancerXx_NEWLINE_xXIs receiving concurrent standard and/or investigational anti-cancer therapy or has received such therapy within a period of 30 days prior to the first scheduled day of dosing (investigational therapy is defined as treatment for which there is currently no regulatory-authority-approved indication); orXx_NEWLINE_xXTreatment with any chemotherapy, radiation therapy, biologics for cancer, or investigational therapy within 14 days of randomizationXx_NEWLINE_xXTreatment with chemotherapy or biological therapy within the previous 3 weeks, radiation or small molecule targeted therapy within the previous 2 weeks.Xx_NEWLINE_xXAll previous cancer therapy including chemotherapy, radiation, hormonal therapy and surgery, must be discontinued ?2 weeks prior to registration.Xx_NEWLINE_xXAny concurrent chemotherapy, immunotherapy, or biologic or hormonal therapy for cancer treatment.Xx_NEWLINE_xXPatient has received any systemic therapy (e.g. chemotherapy, targeted therapy, immunotherapy) or radiotherapy for current breast cancer disease before randomization.Xx_NEWLINE_xXA history of prior radiotherapy, chemotherapy, including infusion or perfusion therapy for current disease or any immunotherapy including tumor vaccines, interferon-alfa, interleukins, levamisole or other biologic response modifiers within the past 4 weeksXx_NEWLINE_xXPrior or ongoing therapy (including chemotherapy, antibody therapy, tyrosine kinase inhibitors, radiotherapy, immunotherapy, hormonal therapy, or investigational therapy) for the treatment of Stage IV non-squamous NSCLCXx_NEWLINE_xXAnti-tumor therapy, including chemotherapy, biologic, experimental, or hormonal therapy within 4 weeks prior to Day 1Xx_NEWLINE_xXPrevious chemotherapy, immunotherapy, chemo-embolization, targeted therapy or investigational agent for malignancy within 4 weeks prior to day 1Xx_NEWLINE_xXConcurrent treatment with other anti-cancer therapyXx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation) with the exception of intravesical therapy at the time of TURBTXx_NEWLINE_xXThe study will be limited to patients who are chemotherapy naive; patients may have received prior systemic or liver-directed local therapies for advanced uveal melanoma as long as those treatments do not involve chemotherapy; this includes, but is not limited to: immunotherapy, targeted therapy, transarterial embolization, radiofrequency ablation, or cryoablation; treatment must be completed at least 28 days prior to initiation of study therapy; radiation therapy is also allowed and must be completed at least 28 days prior to initiation of study therapy; lesions treated via radiation or liver-directed therapy may not be used as target lesions unless they demonstrate growth over a minimum of 3 months on subsequent imagingXx_NEWLINE_xXConcomitant chemotherapy, radiation therapy, immunotherapy, biologic therapy, or hormonal therapyXx_NEWLINE_xXAny concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment, receipt of last dose of an approved anticancer therapy within 21 daysXx_NEWLINE_xXAny previous systemic therapy for B-cell NHL, including chemotherapy, immunotherapy, or steroidsXx_NEWLINE_xXAt least two weeks since receipt of any biological therapy, chemotherapy, and/or radiation therapyXx_NEWLINE_xXTreatment with chemotherapy, hormonal therapy (except hormone replacement therapy, oral contraceptives), immunotherapy, biologic therapy, radiation therapy (except palliative radiation to bony metastases), or herbal therapy as cancer therapy within 4 weeks prior to initiation of DLYE5953AXx_NEWLINE_xXBiologic/Immunologic (anti-neoplastic) therapy: It must be at least 28 days since the completion of therapy with a biologic/immunologic agent such as a monoclonal antibody prior to study enrollment and at least 28 days since non-study chemotherapy has been administered, excluding CNS directed therapy as described in Section 4.1.Xx_NEWLINE_xXPrior chemotherapy, biologic therapy, or investigational therapy for locally recurrent or metastatic HER2 breast cancer.Xx_NEWLINE_xXAny approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3 weeks prior to initiation of study treatmentXx_NEWLINE_xXHas recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy\r\n* Myelosuppressive chemotherapy: At least 3 weeks since completion (6 weeks for nitrosourea)\r\n* Biologic (anti-neoplastic agent): At least 14 days since completion of therapy with a biologic agent\r\n* Radiation (XRT): >= 1 week must have elapsed from prior palliative XRT to non-target lesionsXx_NEWLINE_xXDiscontinuation of all therapy (including radiotherapy, chemotherapy, tyrosine kinase inhibitors (TKIs), immunotherapy, or investigational therapy for the treatment of cancer at least 2 weeks prior to the initiation of study therapyXx_NEWLINE_xXPrior chemotherapy, immunotherapy, investigational therapeutic agent, or other therapy used to treat HCC within 4 weeks before the first scheduled administration of RO7070179.Xx_NEWLINE_xXAny approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment; the following exceptions are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* TKIs approved for treatment of NSCLC discontinued > 7 days prior to cycle 1, day 1; the baseline scan must be obtained after discontinuation of prior TKIsXx_NEWLINE_xXAny concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment.Xx_NEWLINE_xXConcurrent chemotherapy, or targeted anti-cancer agents, other than hydroxyurea, low-dose cytarabine, intrathecal therapy and/or low dose maintenance therapy such as vincristine, mercaptopurine, methotrexate or glucocorticoidsXx_NEWLINE_xXRecent chemotherapy, radiotherapy, hormonal therapy, immunotherapy or investigational drugs within 21 days or 5 half-days from enrolment.Xx_NEWLINE_xXAt least 7 days since the completion of therapy with a biologic agentXx_NEWLINE_xXAny prior systemic therapy (including chemotherapy, antibody therapy, tyrosine kinase inhibitors, immunotherapy, hormonal therapy) before Day 1 of Cycle 1 for treatment of mCRCXx_NEWLINE_xXPatients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy or radiotherapy) concurrently or within 2 weeks of starting LDE225Xx_NEWLINE_xXCancer therapy (chemotherapy with delayed toxicity, extensive radiation therapy, immunotherapy, biologic therapy, or major surgery) or investigational anti-cancer drugs within the last 3 weeks, or chemotherapy without delayed toxicity within the last 2 weeks, preceding the first dose of study medication.Xx_NEWLINE_xXFor Part 1, subjects may have had any number of prior systemic anti-cancer treatments, but may not have received more than 2 schedules of myeloablative chemotherapy. For Parts 2 and 3, more than two prior systemic anti-cancer treatment (chemotherapy, immunotherapy, biologic therapy, vaccine therapy, or investigational treatment) for Stage IIIC (unresectable) or Stage IV (metastatic) melanoma are not permitted. Prior systemic treatment in the adjuvant setting is allowed. (Note: Ipilimumab treatment must end at least 8 weeks prior to Study Day 1 (Parts 1 and 2) or randomization (Part 3.)Xx_NEWLINE_xXFewer than 21 days since last anti-tumor therapy, including chemotherapy, biologic except trastuzumab, experimental, immune, radiotherapy for the treatment of breast cancer, with the following exceptions:\r\n* Hormone therapy \r\n* Palliative radiation therapy involving =< 25% of marrow-bearing bone is allowed if completed within >= 14 days prior to first study treatmentXx_NEWLINE_xXAnti-cancer therapy or investigational anti-cancer therapy or chemotherapy without delayed toxicity within treatment specific timeframe.Xx_NEWLINE_xXConcurrent therapy with any other non-protocol anti-cancer therapyXx_NEWLINE_xXCancer therapy (chemotherapy with delayed toxicity, extensive radiation therapy, immunotherapy, biologic therapy, or major surgery) or investigational anti-cancer drugs within the last 3 weeks, or chemotherapy without delayed toxicity within the last 2 weeks, preceding the first dose of study treatment.Xx_NEWLINE_xXNo prior chemotherapy, hormonal therapy, or radiation therapy for this cancerXx_NEWLINE_xXAny anti-cancer therapy or treatment incorporating chemotherapy, immunotherapy, hormonal therapy, or biologic therapy within 28 days of the start of trial treatment or within 5 times the half life of such treatment, whichever is shorter. Treatment with nitrosoureas or mitomycin C are exceptions to this for which a treatment interval of at least 6 weeks is requiredXx_NEWLINE_xXPatient has concurrent use of anti-neoplastic agents including investigational therapyXx_NEWLINE_xXNo concurrent systemic chemotherapy or anticancer biologic therapy is allowed. Note: Patients on hormonal treatment for breast cancer or prostate cancer may continue on treatment and enter into study.Xx_NEWLINE_xXRadiation, chemotherapy, immunotherapy, any other systemic anticancer therapy or participation in an investigational anti-cancer study ? 3 weeks prior to initiation of therapyXx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation)Xx_NEWLINE_xXPrior anti-cancer therapyXx_NEWLINE_xXPatients must be >= 4 weeks since completing their prior therapy (including surgery, radiation therapy or investigational therapy [including targeted small molecule agents]); all previous clinically significant treatment-related toxicities have resolved to =< grade 1; patients must be >= 4 weeks since prior therapy with an anti-androgen (e.g. casodex, flutamide, enzalutamide or nilutamide)Xx_NEWLINE_xXOther concurrent chemotherapy, radiotherapy, or any ancillary therapy considered investigational; NOTE: bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatmentXx_NEWLINE_xXAny major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 21 days prior to randomization and/or daily or weekly chemotherapy without the potential for delayed toxicity within 14 days prior to randomizationXx_NEWLINE_xXThe subject has received anticancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal, biologic, or any investigational therapy within a period of 28 days prior to the first dose of ABT-414.Xx_NEWLINE_xXAll previous cancer therapy, including radiation, hormonal therapy and surgery, must have been discontinued at least 4 weeks prior to treatment in this studyXx_NEWLINE_xXPrior therapy requirements: \r\n* At least >= 1 prior completed chemotherapy regimen including chemotherapy, biologic, immunologic or targeted therapy\r\n* At least 4 weeks from last dose of prior chemotherapy with resolution of the acute toxic effects of the therapy\r\n* At least 2 weeks from completion of prior radiation therapy\r\n* At least 4 weeks from last dose of prior investigational therapy\r\n* Not receiving any current anti-cancer therapy\r\n* At least 4 weeks from last dose of interferon or IL-2 therapy\r\n* At least 8 weeks from completion of antibody therapy with anti-checkpoint antibodies, such as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and anti-programmed cell death 1 (PD1)\r\n* At least 4 weeks from last dose of prior other biologic agentsXx_NEWLINE_xXOther concurrent chemotherapy, radiotherapy, or any ancillary therapy considered investigational; NOTE: bisphosphonates are considered to be supportive care rather than therapy, and are thus allowed while on protocol treatmentXx_NEWLINE_xXNo prior systemic therapy, immunotherapy, investigational agent, chemoembolization, radioembolization or radiation therapy within the last 4 weeks.Xx_NEWLINE_xXTreatment with continuous or intermittent small molecular therapeutics, biologic therapy or hormonal therapy within 28 days prior to first dose of study treatment.Xx_NEWLINE_xXCurrent use of or anticipated requirement during the study of prohibited medication(s) (any investigational drug(s), Other anti-cancer therapy (chemotherapy, radiation therapy, immunotherapy, biologic therapy, or hormone therapy other than for replacement), AR antagonists (e.g., bicalutamide, flutamide, nilutamide), 5-alpha reductase inhibitors (e.g., finasteride, dutasteride), Androgens (e.g., testosterone, dihydroepiandrosterone), Herbal medication(s) that may affect PSA levels (e.g., saw palmetto), Other herbal medications including, but not limited to: St. John's wort, kava, ephedra (ma huang), gingko biloba, yohimbe and ginseng)Xx_NEWLINE_xXPatients on concurrent anti-cancer therapy other than that allowed in the studyXx_NEWLINE_xXPrior therapy: The subject's disease (i.e. cancer, neurofibromatosis type 1 [NF-1] with plexiform neurofibroma [PN], or Langerhans cell histocytosis [LCH]) must have relapsed after or failed to respond to frontline curative therapy or there must not be other potentially curative treatment options available. Curative therapy may include surgery, radiation therapy, chemotherapy, or any combination of these modalities. All subjects must have recovered to grade <=1 from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to enrollment. Prior therapy includes; myelosuppressive chemotherapy, differentiating agents/ biologic response modifiers (small molecules, antibodies, viral therapies) (anti-cancer agent), non-myelosuppressive anticancer agents, investigational agent, radiation therapy, stem cell transplantation or infusion, number of prior treatment regimens, colony stimulating factors, corticosteroids.Xx_NEWLINE_xXConcurrent anti-cancer therapy (chemotherapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than study treatment (regorafenib)Xx_NEWLINE_xXNo prior hormonal therapy for treatment of cancer within the past 21 daysXx_NEWLINE_xXPatients going on Arm 1 or combination dose cohort must not have received prior radiation therapy, chemotherapy, immunotherapy or therapy with biologic agent (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, tumor infiltrating lymphocytes [TIL], lymphokine-activated killer [LAK] or gene therapy), or hormonal therapy for their brain tumor; glucocorticoid therapy is allowedXx_NEWLINE_xXPatients going on Arm 2 must have received planned treatment with radiation therapy and concomitant temozolomide at least 28 days but no more than 49 days prior to starting treatment on this study; patients must have received at least 80% of planned temozolomide and radiation therapy with no grade 3 or grade 4 toxicity (except lymphopenia) attributed to the temozolomide; Arm 2 patients may not have received any other prior chemotherapy, immunotherapy or therapy with biologic agent (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, TIL, LAK or gene therapy), or hormonal therapy for their brain tumor; prior Gliadel wafers are allowed; glucocorticoid therapy is allowedXx_NEWLINE_xXConcurrent anti-cancer therapy (chemotherapy, hormonal therapy, radiation therapy [other than that specified by the protocol], surgery, immunotherapy, biologic therapy including lapatinib, bevacizumab, tyrosine kinase inhibitors other than sorafenib or tumor embolization); trastuzumab will be allowed to continue for human epidermal growth factor receptor 2 positive (HER2+) patientsXx_NEWLINE_xXOngoing radiation therapy, chemotherapy, hormonal therapy directed at the tumor, immunotherapy, or biologic therapyXx_NEWLINE_xXSubjects who have received anti-cancer therapies within 2 weeks of the start of study drug (including chemotherapy, radiation therapy, immunotherapy, etc.).Xx_NEWLINE_xXTreatment with prohibited medications (eg, concurrent anti-cancer therapy including other chemotherapy, radiation (local radiation for palliative care is permitted), hormonal anti-cancer treatment, biologic therapy, or immunotherapy) < 28 days prior to the first day of study treatmentXx_NEWLINE_xXAny anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, and/or radiotherapy, within 3 weeks prior to initiation of study treatment, with the exceptions as mentioned in the protocolXx_NEWLINE_xXConcurrent treatment or planned treatment with other anticancer therapy (chemotherapy, immunotherapy, radiotherapy, targeted therapy, gene therapy).Xx_NEWLINE_xXPatients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy, or radiotherapy) concurrently or within 2 weeks of starting treatmentXx_NEWLINE_xXAny concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy for cancer treatmentXx_NEWLINE_xXConcurrent immunotherapy, chemotherapy, or radiation therapy for duration of subject participation on studyXx_NEWLINE_xXPrior therapy (including chemotherapy, antibody therapy, tyrosine kinase inhibitors, radiotherapy, immunotherapy, hormonal therapy, or investigational therapy) before Day 1 of Cycle 1 for the treatment of advanced (Stage IV) or recurrent NSCLCXx_NEWLINE_xXPatient who have received chemotherapy, immunomodulatory drugs (e.g., lenalidomide, thalidomide or pomalidomide), immunotherapy, radiation therapy, or any investigational drug(s) within 14 days before enrollment or who have not recovered from the side effects of the therapy to at least grade 1; localized radiation therapy to a single site within 7 days is acceptableXx_NEWLINE_xXTreatment with anti-tumor therapy, including chemotherapy, biologic, experimental or hormonal therapy, within 4 weeks prior to Day 1Xx_NEWLINE_xXAny chemotherapy, radiotherapy, immunotherapy, biologic, investigational or hormonal therapy for treatment of lymphoma within 28 days prior to treatmentXx_NEWLINE_xXSubjects may have received previous courses of an investigational biologic therapy including active or passive immunotherapy greater than 60 days prior to receiving the first injection of DPX-SurvivacXx_NEWLINE_xXSubjects undergoing concurrent chemotherapy, radiation therapy, immunotherapy are excludedXx_NEWLINE_xXAnti-tumor therapy, including chemotherapy, biologic, experimental, or hormonal therapy within 4 weeks prior to study treatmentXx_NEWLINE_xXRadiation therapy, surgery (except major surgery), tumor embolization, chemotherapy, immunotherapy, biologic therapy, investigational therapy, or hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug.Xx_NEWLINE_xXAnti-tumor therapy, including chemotherapy, biologic, experimental, or hormonal therapy, or radiotherapy within 4 weeks prior to Day 1, with the following exceptions: maintenance hormonal therapy for metastatic prostate cancer and palliative radiation to bone metastases within 2 weeks prior to Day 1Xx_NEWLINE_xXReceived prior investigational or non-investigational cytotoxic chemotherapy, hormonal therapy, biological therapy (including but not limited to monoclonal antibodies, small molecules or other immunotherapy) to treat hepatocellular carcinoma.Xx_NEWLINE_xXNeed for concomitant anticancer therapy (surgery, radiation therapy, chemotherapy, immunotherapy, radiofrequency ablation) or other investigational agents during the study treatment period.Xx_NEWLINE_xXAnti-tumor therapy within 28 days of study day 1 including chemotherapy, antibody therapy, retinoid therapy, or other investigational agentXx_NEWLINE_xXAny concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy for cancer treatmentXx_NEWLINE_xXPrior chemotherapy, hormonal therapy, biologic therapy, investigational agent, targeted therapy or radiation therapy for current breast cancerXx_NEWLINE_xXCancer therapy (chemotherapy with delayed toxicity, radiation therapy, immunotherapy, biologic therapy, or major surgery) within the last 3 weeks; chemotherapy regimens without delayed toxicity within the last 2 weeks; or use of any investigational anti-cancer or other drug within 28 days or 5 half-lives, whichever is longer, preceding the first dose of GSK2118436.Xx_NEWLINE_xXPatients who have received prior chemotherapy, immunotherapy, radiotherapy, hormonal therapy or biologic therapy for their ovarian or primary peritoneal cancer are not eligibleXx_NEWLINE_xXConcurrent therapy with any other non-protocol anti-cancer therapyXx_NEWLINE_xXCurrently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy).Xx_NEWLINE_xXPatients with a prior history of chemotherapy, hormonal ablation therapy and/or radiation therapy.Xx_NEWLINE_xXThe subject is receiving concomitant radiotherapy, chemotherapy, other anti-neoplastic therapy, or investigational therapy (other than the investigational therapy under study)Xx_NEWLINE_xXThe subject has received radiation therapy, chemotherapy, other anti-neoplastic therapy, or investigational therapy within 30 days prior to first dose of study drugXx_NEWLINE_xXUse of concomitant chemotherapy, investigational agents, radiation therapy, or immunotherapy other than as specified in the protocolXx_NEWLINE_xXPatients on concurrent anti cancer therapy other than that allowed in the study.Xx_NEWLINE_xXNo prior chemotherapy, hormonal therapy, biologic therapy or radiation therapy for breast cancerXx_NEWLINE_xXConcurrent chemotherapy, radiation therapy, immunotherapy, biologic therapy, or hormonal therapy for treatment of cancer;Xx_NEWLINE_xXNo prior medical therapy (chemotherapy, immunotherapy, biologic or targeted therapy) or radiation therapy for MM, unless locoregionally recurrent; if recurrent, no prior medical or radiation therapy is allowed for the latest recurrenceXx_NEWLINE_xXAny approved systemic anti-cancer therapy (including chemotherapy) or hormonal therapy within 3 weeks prior to initiation of study treatmentXx_NEWLINE_xXAnti-cancer treatment including surgery, radiotherapy, chemotherapy, other immunotherapy, or investigational therapy within 14 days of registrationXx_NEWLINE_xXReceipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) =< 28 days prior to the first dose of study drug (if sufficient wash-out time has not occurred due to the schedule or pharmacokinetics [PK] properties of an agent, a longer wash-out period may be required)Xx_NEWLINE_xXUse of chemotherapy, biologic therapy, radiation therapy, erythropoietin or related erythropoiesis stimulating agents, or investigational therapy within 2 weeks of the first dose of study drugXx_NEWLINE_xXRecovery from effects of recent surgery, radiotherapy, or chemotherapy; patients should be free of active infection requiring antibiotics (with the exception of uncomplicated urinary tract infection [UTI]); any other prior therapy such as radiation therapy, tumor embolization, chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormone therapy, must be discontinued at least 28 days prior to the first dose of pazopanib; at least 28 days must have elapsed since the patient underwent any major surgery (laparotomy, laparoscopy, thoracotomy, video assisted thorascopic surgery-VATS); no restriction on minor procedures (central venous access catheter placement, ureteral stent placement, thoracentesis)Xx_NEWLINE_xXPrior therapy for this cancerXx_NEWLINE_xXAnti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) within 4 weeks prior to entering the study (signing of consent form) or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier; patients on hormonal or bisphosphonate treatment for non-cancer related conditions are eligibleXx_NEWLINE_xXReceived the last administration of an anticancer monoclonal antibody, immunotherapy, hormonal therapy, or chemotherapy (except nitrosoureas and mitomycin-C) =< 28 days prior to study registration or who have not recovered from the side effects of such therapyXx_NEWLINE_xXAnti-cancer therapy within 28 days prior to starting on therapyXx_NEWLINE_xXReceiving or plans to receive concomitant chemotherapy, radiation therapy; immunotherapy or other anti-cancer therapy other than is specified in the protocolXx_NEWLINE_xXNeed for treatment with any conventional modality for prostate cancer (surgery, radiation therapy, and hormonal therapy)Xx_NEWLINE_xXNOTE: concomitant treatment with ongoing trastuzumab (Herceptin) or other targeted/biologic agents is allowed; concomitant treatment with any other type of chemotherapy or hormonal therapy is not allowedXx_NEWLINE_xXNo prior systemic therapy for advanced NSCLC, including chemotherapy, targeted therapy or immunotherapy; prior palliative radiation permitted; prior adjuvant chemotherapy/radiation is permittedXx_NEWLINE_xXCompleted definitive therapy consisting of surgery, chemotherapy or radiation therapy at least 180 days ago (may continue on Herceptin or endocrine therapy)Xx_NEWLINE_xXBe receiving any form of treatment for cancer with the exception of hormonal or biologic therapyXx_NEWLINE_xXHave not received chemotherapy or radiation for > 14 days (advanced cancer patients receiving hormonal therapy, immunotherapy, or targeted therapy that does not come with a recommendation for prophylactic anti-emetic therapy are eligible)Xx_NEWLINE_xXPatients with metastatic cancers who are considering or pursuing additional palliative therapy after progressing on at least two prior lines of chemotherapy, immunotherapy, biological or targeted therapiesXx_NEWLINE_xXPatients who have completed treatment but are within five years of treatment completion (primary surgery, chemotherapy or radiation therapy), whichever was received last; hormonal therapy and targeted therapy are allowedXx_NEWLINE_xXUndergoing chemotherapy, hormonal therapy, or targeted therapyXx_NEWLINE_xXAny concurrent chemotherapy, immune-mediated therapy or biologic or hormonal therapy for cancer treatment Active or prior documented autoimmune disease with some exceptions.Xx_NEWLINE_xXThe last dose of biologic or investigational therapy must be =< 21 days prior to initiation of study therapyXx_NEWLINE_xXTargeted therapy must have been discontinued =< 14 days prior to initiation of study therapyXx_NEWLINE_xXHas had prior systemic therapy, targeted therapy, radiotherapy treatment or radical surgery for head and neck cancer under studyXx_NEWLINE_xXTreatment with chemotherapy, immunotherapy, or biologic therapy as anti-cancer therapy within 3 weeks, or treatment with endocrine therapy or kinase inhibitors within 2 weeks, prior to starting study treatment, except for premenopausal participants with breast cancer who may continue Gonadotropin-releasing hormone agonist therapyXx_NEWLINE_xXPatients must not be planning to receive other biologic therapy, radiation therapy, hormonal therapy, chemotherapy, surgery, or other therapy while on this protocol; palliative radiation therapy or surgery can be considered for symptomatic non-target lesions after discussions with the study teamXx_NEWLINE_xXPrior hormonal therapy is allowed (no washout period is required after hormonal therapy)Xx_NEWLINE_xXHave not completed surgery, chemotherapy, or radiation treatment associated with their diagnosis; a washout period of a minimum of 6 weeks is required from the last anti-cancer treatment received except hormonal therapyXx_NEWLINE_xXParticipants must self-identify as being at least 90 days post final chemotherapy, biologic therapy, or radiation therapy treatment and/or breast surgery; current use of hormonal therapy is permitted (e.g., tamoxifen and aromatase inhibitors)Xx_NEWLINE_xXPost active breast cancer therapy (e.g. surgery and/or chemotherapy and/or radiation therapy), but may still be undergoing maintenance cancer therapy and must be within 4 years of end of active treatment.Xx_NEWLINE_xXReceiving systemic cancer therapy (including conventional chemotherapy, novel/targeted agents, immunotherapy, monoclonal antibody therapy, oral tyrosine kinase inhibitors, or hormonal agents) OR will begin systemic therapy within the next 4 weeks OR has received systemic therapy and reports that they are still experiencing side effects or complications of the cancer or cancer treatmentXx_NEWLINE_xXFor those receiving chemotherapy/infusional therapy, patients have to enroll during the 4 weeks prior to or on the day of treatment initiation; for those enrolling during hormonal therapy and/or radiation, patients must enroll within 6 months of diagnosis of breast cancer, defined as the date of initial biopsy; patient may be receiving hormonal therapy, radiation therapy, or both at the time of enrollmentXx_NEWLINE_xXUndergone cancer treatment (excluding hormonal therapy or biological maintenance therapy) in the 4 weeks prior to enrollmentXx_NEWLINE_xXExpected to require cancer treatment, other than biologic or hormonal maintenance therapy, during the course of the studyXx_NEWLINE_xXHave completed all cancer-related treatments (i.e., surgery, chemotherapy, radiotherapy, immunotherapy, etc.) except for hormonal therapy and Herceptin at least one year previouslyXx_NEWLINE_xXPatients’ post-operative treatment must have included at least 80% of standard radiation and concomitant temozolomide; patients may not have received any other prior chemotherapy, immunotherapy or therapy with biologic agent (including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons, interleukins, tumor infiltrating lymphocytes [TIL], lymphokine-activated killer [LAK] or gene therapy), or hormonal therapy for their brain tumor; prior Gliadel wafers are allowed; glucocorticoid therapy is allowedXx_NEWLINE_xXPatients must not have received prior radiation therapy, systemic chemotherapy, immunotherapy, therapy with biologic agents or hormonal therapy for their brain tumorXx_NEWLINE_xXMust be considering or currently receiving any kind of cancer treatment (any line), including but not limited to hormonal treatment, chemotherapy, monoclonal antibody therapy, or targeted therapy; patients who are considering therapy are eligible even if they ultimately choose not to be on therapy; patients with a history of any previous cancer treatment, including radiation and/or surgery are eligible; a patient may also be enrolled on a treatment trial and participate in this study, if all other inclusion and exclusion criteria are metXx_NEWLINE_xXPrior treatment with Scrambler therapyXx_NEWLINE_xXConcurrent radiation, chemotherapeutic, or investigational therapy other than transplant related therapyXx_NEWLINE_xXMust have received systemic therapy for their breast cancer (anti-estrogen and/or chemotherapy)\r\n* Chemotherapy must be complete prior to entry\r\n* Anti-estrogen therapy may be ongoingXx_NEWLINE_xXConcurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than regorafenibXx_NEWLINE_xXCurrently between 1.0 and 4.99 years from the completion of active cancer-directed therapy (cytotoxic chemotherapy, radiation therapy and/or definitive surgical intervention)Xx_NEWLINE_xXAny concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment. Concurrent use of hormones for non-cancer-related conditions is acceptable.Xx_NEWLINE_xXClose proximity in time to treatment with high-dose chemotherapy, stem-cell rescue, differentiation therapy, immunotherapy, thoracic or mediastinal radiotherapy, hormonal therapy, biologic therapy, herbal cancer therapy, hematopoietic growth factor, investigational therapy, or St. John's wort according to protocol-defined criteria prior to initiation of study drugXx_NEWLINE_xXPatients receiving cancer therapy (i.e., chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization) within 2 weeks of cycle 1/day 1 with the following exceptions:\r\n* Corticosteroid therapy (prednisone or equivalent =< 20 mg daily) is allowed as clinically warranted as long as the dose is stabilized at least for 7 days prior to initial dosing; topical or inhaled corticosteroids are permitted\r\n* Patients who may experience clinical deterioration may start therapy after a shorter washout period with prior approval by the principal investigator (PI)Xx_NEWLINE_xXNo prior treatment involving irradiation, hormonal therapy, immunotherapy, investigational therapy, and/or other concurrent agents or therapies for ovarian cancerXx_NEWLINE_xXConcurrent anti-cancer therapyXx_NEWLINE_xXNo previous chemotherapy, endocrine, therapy or radiation therapy with therapeutic intent for this cancerXx_NEWLINE_xXParticipant has received anti-cancer therapy including chemotherapy, immunotherapy, biologic or any investigational therapy within a period of 21 days prior to Study DayXx_NEWLINE_xXAny approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3 weeks prior to initiation of study treatment, with the exceptions provided in the protocolXx_NEWLINE_xXPatients who are receiving other anti-neoplastic therapy (e.g. chemotherapy, targeted therapy or radiotherapy) concurrently or within 2 weeks of starting treatment with LDE225Xx_NEWLINE_xXThose prescribed a hormonal therapy for cancerXx_NEWLINE_xXConcomitant biologic, hormonal, or radiation therapy are acceptableXx_NEWLINE_xXCONTROL (HEALTHY) GROUP: Never received chemotherapy, radiation therapy, immunotherapy, or had breast surgeryXx_NEWLINE_xXPatients must be at least 28 days post cytotoxic chemotherapy, radiotherapy, monoclonal antibody and/or other biologic therapy, prior to enrollment; patients on bisphosphonates, denosumab, and/or endocrine therapy and may continue throughout duration of studyXx_NEWLINE_xXParticipants must be at least 6 months from any prior cancer-directed treatment (such as surgical resection, chemotherapy, immunotherapy, hormonal therapy or radiation).Xx_NEWLINE_xXPatients currently using anti-neoplastic or anti-tumor agents, including chemotherapy, radiation therapy, immunotherapy, and hormonal anticancer therapyXx_NEWLINE_xXAre currently undergoing treatment for cancer with chemotherapy, hormone therapy, radiation, or biological therapyXx_NEWLINE_xXHave undergone treatment of hormone therapy, immunotherapy, chemotherapy and/or radiation for any malignancies within the past 2 yearsXx_NEWLINE_xXParticipants must be at least 6 months from any prior cancer-directed treatment (such as surgical resection, chemotherapy, immunotherapy, hormonal therapy or radiation)Xx_NEWLINE_xXConcurrent use of hormonal contraception or hormone replacement therapyXx_NEWLINE_xXAt least 4 weeks since the last dose of chemotherapy, immunotherapy, surgery, or radiation therapy (exception: patients may have received palliative low dose radiation therapy one week before treatment provided it is not given to the only targeted lesions); at least 6 weeks for therapy which is known to have delayed toxicity (nitrosoureas, mitomycin-C, and liposomal doxorubicin); at least 4 weeks (or 5 half-lives, whichever is shorter) since treatment with biologic/targeted therapies; at least 2 weeks since last hormonal therapyXx_NEWLINE_xXChemotherapy, radiation therapy, hormonal therapy, immunotherapy or biological therapy, or investigational agent within 21 daysXx_NEWLINE_xXAny major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 21 days prior to enrollmentXx_NEWLINE_xXAnticipate needing secondary prostate cancer therapy within the next 6 months (i.e. radiation, or hormonal therapy)Xx_NEWLINE_xXTreatment including radiation therapy, chemotherapy, biotherapy, or hormonal therapy for this cancer prior to surgery (i.e., any neoadjuvant chemotherapy or endocrine therapy is not allowed); patients who undergo surgical resection with breast conservation and then are treated with adjuvant systemic therapy are eligible to enroll prior to the start of radiotherapyXx_NEWLINE_xXReceipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal antibodies, other investigational agent) < 21 days prior to enrollmentXx_NEWLINE_xXAnticancer treatment, including endocrine therapy, radiotherapy, chemotherapy, biologic therapy, or therapy in an investigational clinical study, ? 14 days prior to the date of RandomizationXx_NEWLINE_xXSubjects with head and neck cancer involving the oropharynx or oral cavity, who are expected to undergo high dose radiation therapy (i.e., ? 60 Gy) that typically results in oral mucositis, with or without concurrent chemotherapy or biologic targeted therapy.Xx_NEWLINE_xXPatients must have completed primary breast or ovarian cancer therapy (i.e., surgery, chemotherapy, immunotherapy and/or radiation therapy as appropriate per standard of care for patient's specific cancer)Xx_NEWLINE_xXConcurrent anti-cancer therapy (chemotherapy, hormonal therapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than sorafenib, and protocol-specified whole-brain radiotherapyXx_NEWLINE_xXPatients who are planned to receive either chemotherapy, targeted therapy, immunotherapy, or no additional cancer-directed drug therapyXx_NEWLINE_xXDiagnosis of cervical cancer of any stage that will be treated with radiation therapy and concurrent chemotherapyXx_NEWLINE_xXSUB-STUDY III: Radiation therapy or start of standard of care systemic therapy (chemotherapy, androgen deprivation therapy) within 14 days prior to study PETXx_NEWLINE_xXAnti-cancer treatment (chemotherapy and/or radiation therapy) within the last 2 weeksXx_NEWLINE_xXMay or may not be on hormonal therapy, chemotherapy, or radium therapy; if on hormonal therapy or chemotherapy, must be on it for at least 3 monthsXx_NEWLINE_xXNo plans to undergo prostate cancer (PCa) therapy (with hormone therapy, chemotherapy, radium therapy, or external radiation) between the two study examsXx_NEWLINE_xXPatients already scheduled to receive conventional radiotherapy, chemotherapy, biological therapy, vaccine therapy, or surgery as treatment (except at disease progression)Xx_NEWLINE_xXPatients participating treatment trials including targeted therapy, experimental therapy or immunotherapy are also eligibleXx_NEWLINE_xXConcurrent therapy will be allowedXx_NEWLINE_xXMust not have treatment with any of the following anti-cancer therapies:\r\n* Radiation therapy, surgery or tumor embolization within 14 days prior to the first dose of pazopanib OR\r\n* Chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days prior to the first dose of pazopanib\r\n* Treatment with prior sorafenib, sunitinib, temsirolimus or everolimus is allowed but must be discontinued at least 5 days prior to beginning pazopanibXx_NEWLINE_xXPatients who are potential candidates to receive neoadjuvant therapy with either chemotherapy alone, radiation alone, immunotherapy alone, or combined treatment with any of these modalities; if on therapy, patients in whom a new treatment protocol or modality is being considered would be eligibleXx_NEWLINE_xXSubject must not have received any prior treatment, including chemotherapy, biological therapy, or targeted therapy for metastatic pancreatic adenocarcinoma, with the following exceptions and notes:Xx_NEWLINE_xXConcurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, hormonal therapy, biological therapy) other than the ones specified in the protocol; any other investigational drugs should be discontinued 2 weeks prior to the first dose of study medicationXx_NEWLINE_xXReceived treatment with chemotherapy, radiation, or biologic cancer therapy within 14 days of first protocol treatment; prior and concurrent hydroxyurea is permittedXx_NEWLINE_xXAnticipated use of concomitant chemotherapy (other than the protocol-specified agents), immunotherapy, or radiation therapyXx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study\r\n* Myelosuppressive chemotherapy: must not have received within 3 weeks of entry onto this study\r\n* Biologic (anti-neoplastic agent): at least 7 days since the completion of therapy with a biologic agent\r\n* Immunotherapies: at least 42 days must have elapsed since a prior therapy that included a monoclonal antibody or any other type of immunotherapy (e.g. chimeric antigen receptor [CAR] T cell therapy)\r\n* Radiation therapy (RT): >= 2 weeks for local palliative RT (small port); >= 6 months must have elapsed if prior craniospinal RT or if >= 50% radiation of the pelvis; >= 6 weeks must have elapsed if other substantial bone marrow (BM) radiationXx_NEWLINE_xXPrevious hormonal therapy is allowedXx_NEWLINE_xXThe subject has had preoperative chemotherapy, immunotherapy, or radiation therapy within the 30 days prior to Lymphoseek administrationXx_NEWLINE_xXPatients cannot have hormonal cancer therapy or radiation therapy as prior cancer treatment within 5 years of registration; (prior surgery, biologic therapy, hormonal therapy, or radiation therapy for a malignancy over 5 years prior to enrollment that is not considered cured is acceptable)Xx_NEWLINE_xXReceived treatment with chemotherapy, wide-field radiation, or anti-cancer biologic therapy including investigational agents within 14 days of study entry.Xx_NEWLINE_xXAre currently taking any hormonal therapy or have been on hormonal therapy in the past 4 weeksXx_NEWLINE_xXPatients may receive no other concurrent anticancer treatments such as chemotherapy, hormone therapy (except for prostate cancer patients on luteinizing hormone-releasing hormone ((LHRH)) agonists), immunotherapy, biological agents, investigational agents, or radiation therapy during this trial, and should be off these treatments for at least 2 weeks, or until they have completely recovered from the side effects of these treatments, whichever is longest, except for persistent grade 1 neuropathy in patients who received prior platinum or taxanes.Xx_NEWLINE_xXChemotherapy, biologic therapy, radiation therapy or immunotherapy within 3 weeks prior to dosing with amatuximabXx_NEWLINE_xXAny major surgery, extensive radiotherapy, chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 30 days of enrollment and/or daily or weekly chemotherapy without the potential for delayed toxicity within 14 days of enrollmentXx_NEWLINE_xXHave discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, cancer-related hormonetherapy, and investigational therapy) for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug and have recovered from the acute effects of therapy(treatment related toxicity resolved to baseline), except for residual alopeciaXx_NEWLINE_xXPrior chemotherapy, biological therapy, radiation therapy, androgens, thalidomide, immunotherapy, other anticancer agents, and any investigational agents within 14 days of starting study treatment (not including palliative radiotherapy at focal sites)Xx_NEWLINE_xXprior immunotherapyXx_NEWLINE_xXPatients must be registered prior to or on the same day as their first cycle of chemotherapy for their current disease and stage (or disease setting); patient must not have had any systemic therapy (chemotherapy or combination regimens) in the 180 days just prior to registration; prior biologic therapy, immunotherapy, and hormonal therapy are allowedXx_NEWLINE_xXCompletion of prior chemotherapy, biologic therapy, immunotherapy, or radiation therapy at least 4 weeks prior to enrollment.Xx_NEWLINE_xXPrior chemotherapy, radiotherapy, biological cancer therapy, targeted therapy, or major surgery within 28 days prior to enrollment or has not recovered to CTCAE grade 1 or better from adverse event due to cancer therapy administered more than 28 days prior to enrollment.Xx_NEWLINE_xXThe participant is receiving concurrent treatment with other anticancer therapy, including chemotherapy, immunotherapy, hormonal therapy, radiation therapy (RT), chemoembolization, or targeted therapy. Participants receiving palliative radiation therapy to bony metastases prior to the first dose of study medication are eligible.Xx_NEWLINE_xXThe participant is receiving concurrent treatment with other anticancer therapy, including chemotherapy, immunotherapy, hormonal therapy,radiation therapy ( RT), chemoembolization, or targeted therapy. Participants receiving palliative radiation therapy to bony metastases prior to the first dose of study medication are eligible.Xx_NEWLINE_xXAny approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3 weeks prior to initiation of study treatmentXx_NEWLINE_xXPatients that have previously received an ALK TKI or PD-1/PD-L1 therapy, and patients currently receiving cancer therapy (i.e., other targeted therapies, chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization).Xx_NEWLINE_xXHas had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study day 1; Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapyXx_NEWLINE_xXHas received prior targeted small molecule therapy, radiation therapy or systemic chemotherapy for urothelial bladder cancer including neoadjuvant chemotherapy\r\n* Prior intravesical chemotherapy or intravesical immunotherapy is permissible, however, no prior intravesical therapy is permitted within 4 weeks of study enrollment; adjuvant therapy is not permittedXx_NEWLINE_xX